

REVIEW

Open Access

# Antimicrobial resistance crisis: could artificial intelligence be the solution?

Guang-Yu Liu<sup>1†</sup>, Dan Yu<sup>2†</sup>, Mei-Mei Fan<sup>1</sup>, Xu Zhang<sup>3,4</sup>, Ze-Yu Jin<sup>5</sup>, Christoph Tang<sup>6\*</sup> and Xiao-Fen Liu<sup>7\*</sup>

## Abstract

Antimicrobial resistance is a global public health threat, and the World Health Organization (WHO) has announced a priority list of the most threatening pathogens against which novel antibiotics need to be developed. The discovery and introduction of novel antibiotics are time-consuming and expensive. According to WHO's report of antibacterial agents in clinical development, only 18 novel antibiotics have been approved since 2014. Therefore, novel antibiotics are critically needed. Artificial intelligence (AI) has been rapidly applied to drug development since its recent technical breakthrough and has dramatically improved the efficiency of the discovery of novel antibiotics. Here, we first summarized recently marketed novel antibiotics, and antibiotic candidates in clinical development. In addition, we systematically reviewed the involvement of AI in antibacterial drug development and utilization, including small molecules, antimicrobial peptides, phage therapy, essential oils, as well as resistance mechanism prediction, and antibiotic stewardship.

**Key words** Antibiotic, Artificial intelligence (AI), Clinical development, Machine learning (ML), Antimicrobial peptide, Phage therapy, Antibiotic stewardship

## Background

Antimicrobial resistance (AMR) is a natural phenomenon wherein microorganisms, including bacteria, viruses, fungi, and parasites, develop the ability to survive the drugs designed to kill them. The misuse and overuse of antibiotics in human medicine, animal agriculture, and the environment have accelerated the emergence and spread of AMR. This phenomenon renders once-effective treatments ineffective, leading to prolonged illnesses, increased mortality rates, and higher healthcare costs. Thus, AMR is a serious and foremost global threat to human health that requires practical actions urgently. The Global Antimicrobial Resistance and Use Surveillance System launched by the World Health Organization (WHO) revealed that AMR is on the rise and already a leading cause of death [1,2]. Globally, it was estimated that, in 2019 alone, approximately 4.95 million deaths were linked to bacterial AMR, with 1.27 million deaths specifically attributed to bacterial AMR [1]. The highest all-age death rate due to resistance was observed in Western sub-Saharan Africa,

with 27.3 deaths per 100,000 individuals (20.9–35.3) [1]. According to the data from the Centers for Disease Control and Prevention report, AMR to at least first-line antibiotics accounts for more than two million infections in the US alone each year and at least 23,000 deaths [3]. There were more than 2.8 million infections caused by antibiotic-resistant bacteria in the US in 2019 [4]. It is estimated that AMR will cause 10 million deaths each year by 2050 [5]. The Infectious Disease Society of America has highlighted 6 pathogens including *Enterococcus faecium*, *Staphylococcus aureus* (*S. aureus*), *Klebsiella pneumoniae* (*K. pneumoniae*), *Acinetobacter baumannii* (*A. baumannii*), *Pseudomonas aeruginosa* (*P. aeruginosa*) and *Enterobacter* spp. as “ESKAPE” organisms, which pose the highest threat to human lives, owing to their fast-growing antibiotic resistance [6]. The WHO has published an antibiotic-resistant “priority pathogen” list to help drug developers target the pathogens that urgently need novel antibiotics. AMR has also become a public health concern in China. According to data from the Chinese Antimicrobial Surveillance Network, the resistance rate of carbapenem-resistant Gram-negative bacteria has shown a significant increase. Notably, carbapenem-resistant *A. baumannii* has risen from 39.0% to 71.9%, while carbapenem-resistant *K. pneumoniae* has surged from 2.9% to 24.2% from 2005 to 2022 [7]. Additionally, methicillin-resistant *S. aureus* has been consistently detected at a high rate

<sup>†</sup>Guang-Yu Liu and Dan Yu contributed equally to this work

\*Correspondence: christoph.tang@path.ox.ac.uk; xiaofenliu@fudan.edu.cn

<sup>6</sup>Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK

<sup>7</sup>Institute of Antibiotics, Huashan Hospital, Fudan University, Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of the People's Republic of China, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China

Full list of author information is available at the end of the article

of approximately 30% in recent years ([www.chinets.com](http://www.chinets.com))[7].

The number of novel antibiotics developed and approved has gradually decreased over the past decade, with only 4 novel antibiotics approved between 2010 and 2014[8], resulting in limited treatment options for antibiotic-resistant bacterial infections in clinics. Historically, antibiotics were mostly discovered by screening secondary metabolites with antibacterial activities from soil microbes[9]. Unfortunately, the discovery of novel antibiotics is becoming increasingly difficult due to the rediscovery problem where identical compounds were isolated repeatedly[10]. Thus, new drug development is insufficient to meet the demands of clinical treatment, especially for those pathogens on the WHO priority list. Artificial intelligence (AI), a field of computer science, refers to the development of intelligent machines capable of executing tasks typically requiring human-like intelligence in an objective fashion[11]. AI technologies present innovative approaches and have increasingly integrated into a wide range of disciplines to accelerate scientific discoveries, especially in medicine where AI has empowered the discovery of novel drugs and expedited the overall drug development and clinical research process[12-14]. Without exceptions, AI

has constituted a central part of concerted interdisciplinary efforts to tackle the crisis of AMR[15]. In this review, we will discuss the progress and challenges of antibacterial drugs in clinical and preclinical development, as well as novel AI-based methodologies in antibacterial drug development, with a particular focus on new drug design, structure optimization, and exploration of new mechanisms of action (MOA).

### Antibacterial agents in clinical development

The development of new drugs is a time-consuming and resource-intensive process that involves synthesizing thousands of chemicals derived from existing drugs or mechanisms. This is followed by preliminary activity and toxicity screening to identify one or two potential candidates. The existing development of new antibacterial treatments is far from adequate to address the rapid increase of antibiotic resistance, according to the WHO's annual report on the pipeline of drugs. From 2014 to the end of 2021, 18 antibiotics, including one for the treatment of extensively drug-resistant tuberculosis, have been approved and available (Table 1). Among these antibiotics, 16 were approved by the US Food and Drug Administration (FDA), 12 were approved by the

**Table 1 Approved antibiotics from 2014 to 2021**


| Drug   | Target pathogen                              | Class   | Approval year | Approved by        |
|--|--|---|---------------|--------------------|
| Dalbavancin                                  | Gram-positive pathogens                      | Glycopeptide                                  | 2014          | US FDA; EMA        |
| Tedizolid                                    | Gram-positive pathogens                      | Oxazolidinone                                 | 2014          | US FDA; EMA        |
| Oritavancin                                  | Gram-positive pathogens                      | Glycopeptide                                  | 2014          | US FDA             |
| Ceftolozane/tazobactam                       | $\beta$ -lactamase enzyme producing bacteria | $\beta$ -lactam/ $\beta$ -lactamase inhibitor | 2014          | US FDA; EMA        |
| Cefazidime/avibactam                         | CRE  | $\beta$ -lactam/ $\beta$ -lactamase inhibitor | 2015          | US FDA; EMA        |
| Isavuconazonium                              | Antifungal                                   | Triazole                                      | 2015          | US FDA             |
| Delafloxacin                                 | Gram-positive pathogens                      | Fluoroquinolone                               | 2017          | US FDA; EMA        |
| Vaborbactam/meropenem                        | CRE  | $\beta$ -lactam/ $\beta$ -lactamase inhibitor | 2017          | US FDA; EMA        |
| Plazomicin                                   | CRE  | Aminoglycoside                                | 2018          | US FDA             |
| Eravacycline                                 | CRE  | Tetracycline                                  | 2018          | US FDA; EMA        |
| Omadacycline                                 | MRSA and CRE                                 | Tetracycline                                  | 2018          | US FDA             |
| Relebactam+imipenem/<br>Cilastatin/ilastatin | CRE and potential activity for CRPA          | $\beta$ -lactam/ $\beta$ -lactamase inhibitor | 2019          | US FDA; EMA        |
| Lefamulin                                    | MSSA   | Pleuromutilin                                 | 2019          | US FDA; EMA        |
| Pretomanid                                   | XDR-TB                                       | Nitroimidazole                                | 2019          | US FDA; EMA        |
| Lascufloxacin                                | Gram-positive pathogens                      | Fluoroquinolone                               | 2019          | PMDA               |
| Cefiderocol                                  | CRAB, CRPA, and CRE                          | Siderophore $\beta$ -lactam (cephalosporin)   | 2019          | US FDA; EMA        |
| Levonadifloxacin                             | Gram-positive pathogens                      | Fluoroquinolone                               | 2020          | CDSCO              |
| Contezolid                                   | MRSA   | Oxazolidinone                                 | 2021          | US FDA; EMA; China |

CRE. Carbapenem-resistant *Enterobacteriaceae*; MRSA. Methicillin-resistant *Staphylococcus aureus*; CRPA. Carbapenem-resistant *Pseudomonas aeruginosa*; MSSA. Methicillin-susceptible *Staphylococcus aureus*; XDR-TB. Extensively drug-resistant tuberculosis; CRAB. Carbapenem-resistant *Acinetobacter baumannii*; FDA. Food and Drug Administration; EMA. European Medicines Agency; PMDA. Pharmaceuticals and Medical Devices Agency; CDSCO. Central Drugs Standard Control Organization

European Medicines Agency, 1 was approved by the Central Drugs Standard Control Organization of the Government of India, 1 (contezolid) by Chinese National Medical Products Administration, and 1 by Pharmaceuticals and Medical Devices Agency (Japan). Moreover, only vaborbactam and lefamulin have new MOA. The rest of the antibiotics belong to

known classes, including fluoroquinolones (3/16),  $\beta$ -lactam/ $\beta$ -lactamase inhibitors (3/16), glycopeptides (2/16), tetracyclines (2/16), oxazolidinones (2/16), aminoglycosides (1/16), nitroimidazoles (1/16), triazoles (1/16), and siderophore  $\beta$ -lactams (1/16) (Fig. 1).

According to WHO's reports, there was a total of 42 new



therapeutic agents in 2017 (including 33 antibiotics targeting bacterial priority pathogens and 9 biologics), and 59 in 2021 (27 antibiotics and 32 biologics)[16,17], indicating a rapid increase of biologics (including monoclonal antibody, phage endolysin, polyclonal antibody, etc.) development over traditional antibiotics in recent years. These biologics were developed in response to the growing demand for novel antibacterial agents with new targets and MOA. These biologics have promoted a shift of developers' focus from targeting narrow-spectrum agents to a single pathogen specifically. However, there are only 6 of the 27 antibiotics (including New Drug Application, and I–III Phase clinical trials) considered to be innovative drugs according to WHO criteria[17]. Although almost half of them are still  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations, they were markedly safer and more promising combinations for treating infections caused by Gram-negative bacteria[18]. As for extensively drug-resistant Gram-negative bacterial infections, only tigecycline (2005 approved by the FDA and available in China since 2010), polymyxins (which reentered the Chinese market in 2017), and ceftazidime/avibactam (2019) are available clinically.

#### Polymyxin derivatives in clinical development

Polymyxins, which belong to lipopeptides, are considered

as last-line antibiotics and have raised great interest from scientists and pharmaceutical companies to optimize their efficacy and toxicity. Polymyxins are cyclic lipopeptides with 5 positively charged 2,4-diamino butyric acid groups[19]. They are an old class of antibiotics developed in the 1950s and were replaced by other safer antibiotics due to their renal toxicity[20]. However, the emergence of extensively-resistant Gram-negative bacteria, which are resistant to multiple classes of antibiotics and only susceptible to one or two antibiotics, has posed significant challenges to clinics. Polymyxins, with a susceptible rate as high as 98% against these extensively-resistant Gram-negative bacteria, were re-introduced into clinical practice and are now regarded as a last-line of defense against carbapenem-resistant Gram-negative bacteria[21,22]. There are 2 polymyxins used in clinics: the prodrug colistimethate (the active form is colistin or polymyxin E) and polymyxin B sulfate. The structures of components of polymyxin E and polymyxin B are similar, and they possess similar antibacterial activity[21]. Polymyxins can interact with the negatively charged lipid A of lipopolysaccharide and lead to the disruption of the cell membrane and, ultimately, cell death[23]. Nevertheless, dose-limiting nephrotoxicity (due to the reabsorption in renal tubular cells) and their

narrow therapeutic window are key factors hampering the use of polymyxins in clinical settings[24-27]. Furthermore, the poor tissue distribution of polymyxins in the lung after intravenous administration results in low efficacy in pulmonary infections[28-30]. Recent drug development therefore has focused on optimizing the structure of polymyxins, with the hope to obtain drug candidates with better efficacy profiles and less renal toxicity. Of note, several derivatives of polymyxins are in clinical development, specifically targeting carbapenem-resistant *A. baumannii*, *P. aeruginosa*, and *K. pneumoniae* and are expected to have an improved therapeutic window[31-33].

Based on the structure-activity relationships (SAR), polymyxin derivatives were synthesized and screened for their antibacterial activity, cytotoxicity and renal toxicity. SPR206, a novel polymyxin derivative with an amine-containing N-terminal moiety, was shown to have high antimicrobial activity against carbapenem-resistant Gram-negative bacteria and lower kidney cell cytotoxicity (11.6-fold less cytotoxic in HK-2 kidney cells than polymyxin B)[31]. Furthermore, it exhibits reduced *in vivo* nephrotoxicity, as indicated by biomarker levels (including KIM-1, cystatin-C, and albumin in urine) after a 25 mg/kg dose regimen for SPR206, similar to those for polymyxin B at 12.5 mg/kg dose[34]. SPR206 showed lower minimum inhibitory concentrations (MICs) (0.12 mg/L to 0.50 mg/L) than polymyxins against *A. baumannii*, *K. pneumoniae*, and *P. aeruginosa*[34,35]. The drug has now completed first-in-human studies, which evaluated its safety, tolerability, and pharmacokinetics in healthy subjects[31]. Single dose escalation from 10 mg to 400 mg, multiple dosing (every 8 h for 7 d), and multiple doses of 100 mg (every 8 h for 14 d) were safe and well tolerated in healthy subjects[31]. SPR206 demonstrated a urinary recovery of up to 50% in critically ill patients[31], whereas polymyxin B only showed a urinary recovery of 4% in critically ill patients[36] and 4%–8% in healthy subjects[37]. The higher urinary recovery highlights improved safety and hence the potential clinical application of urinary tract infections (UTIs) for SPR206.

According to the interactions between polymyxins and lipid A, a SAR-based mechanistic model was built to evaluate and design new structures with potent antimicrobial activity[38]. By applying this model, combining with the structure-toxicity relationship (STR) and the structure-pharmacokinetic relationship (SPR), a synthetic lipopeptide F365 (QPX9003) was developed[32]. Benefitting from the optimization of non-conserved positions in the polymyxin scaffold, QPX9003 is considered a success in uncoupling therapeutic efficacy from toxicity. Compared to available polymyxins, this compound has

a wider therapeutic window, with up to a 4-fold increase in the maximal tolerable dose relative to polymyxin B and colistin in an acute toxicity mouse model. Additionally, it demonstrated reduced nephrotoxicity, as there was no sign of nephrotoxicity even at a dose up to 72 mg/(kg·d) in mouse model[32]. It also displayed distinct pharmacological characteristics, with more than 3-fold free drug exposure and at least 4-fold urinary recovery compared to polymyxin B[32]. Furthermore, it showed improved drug exposure in the lung with eightfold lower lung surfactant binding to achieve efficacious drug exposure. Currently, the compound has entered Phase I clinical trials[32].

MRX-8, a novel polymyxin analog, possesses a fatty acyl tail attached to its polymyxin B scaffold *via* an ester bond[39]. The ester bond can be cleaved to yield tail-less and less toxic metabolites[40]. MRX-8 was designed to treat multidrug-resistant Gram-negative bacteria and alleviate renal toxicity by breaking its ester bond[33]. It was developed by applying a “soft drug design” approach, which aims to design less toxic drugs with a wider therapeutic window[41]. *In vitro* studies identified the MIC<sub>50</sub> and MIC<sub>90</sub> values of MRX-8 against Gram-negative isolates collected from 2017–2020 in the United States (1314 clinical isolates from the SENTRY Antimicrobial Surveillance Program[42]), which were 0.12 mg/L and 0.25 mg/L, respectively, against *Enterobacterales*; and 0.5 mg/L and 1.0 mg/L, respectively, against *A. baumannii* and *P. aeruginosa*[43]. Among 765 clinical isolates randomly collected from 2017 to 2020 in China, the MIC<sub>50</sub>/MIC<sub>90</sub> of MRX-8 was 0.060/0.125 mg/L, respectively, for carbapenem-resistant *Escherichia coli* (*E. coli*) isolates; 0.125/0.500 mg/L, respectively, for carbapenem-resistant *K. pneumoniae* isolates; 1/1 mg/L, respectively, for carbapenem resistant *P. aeruginosa*[44]. The lower MIC values of MRX-8 demonstrated its effectiveness against clinically isolated Gram-negative bacteria, including carbapenem-resistant *E. coli*, *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii*. This underscores its potential as valuable therapeutics. More importantly, in neutropenic mouse thigh and lung models, MRX-8 demonstrated potent activity against *P. aeruginosa*, *A. baumannii*, *K. pneumoniae*, and *E. coli* infection before entering a Phase I clinical trial[33,43].

#### **Antimicrobial peptides (AMPs) in clinical development**

New antimicrobial biologicals mainly include antibodies, bacteriophages, phage-derived enzymes, and AMPs. AMPs, usually composed of 2–50 amino acids, are produced by multicellular organisms as a defense mechanism against pathogenic microbes[45]. AMPs exert antimicrobial activities through direct interactions with bacterial membranes, which

lead to membrane perturbation and disruption of membrane-associated physiological events such as cell wall synthesis, cell division, and translocation across the membrane[46]. A growing body of research is focused on developing AMPs in addressing AMR for several reasons. Firstly, during infections, bacteria frequently reside in biofilms, which are extracellular polymeric matrices that display high resistance to antibiotics[47]. AMPs could outperform traditional antibiotics in this regard as they possess anti-biofilm activities[48]. Secondly, AMPs also act as important effectors and regulators of the innate immune system. They can enhance phagocytosis, wound healing, and angiogenesis, as well as have adjuvant activity in promoting the development of adaptive immunity against an invading pathogen[49,50].

Examples of important peptides that exhibit potent antimicrobial activities include  $\beta$ -hairpin peptides[51], polyphemusin I[52], and IB-367 (iseganan, which failed in Phase III clinical trials for indications of oral mucositis)[53]. These AMPs have either been discovered, modified, or designed using AI, and they serve as exemplars of the potential of applying AI in the design of novel peptides against drug-resistant bacteria. Some examples of peptides have entered clinical development and the Investigational New Drug Application phase. According to the 2021 WHO report, out of 217 chemicals investigated, 15.2% are direct-acting peptides ( $n=33$ ), compared with direct-acting small molecules (41.5%,  $n=90$ ) and other non-traditional chemicals (42.4%,  $n=92$ )[16] (Fig. 1). The report demonstrated an increasing prevalence of biologicals in both clinical and preclinical product pipelines. Moreover, the preclinical agents predominantly targeted *P. aeruginosa* or *S. aureus*, showing a clear shift from broad-spectrum antibiotics to narrow-spectrum agents focusing on a single pathogen[16].

Reltecimod (AB103) is a synthetic octapeptide, which is a mimetic of the second CD28 dimer interface domain[54]. CD28 is an antigen expressed on CD4<sup>+</sup> and CD8<sup>+</sup> T cells, which can enhance the release of cytokines, including interleukin (IL)-2 and IL-4[55]. Reltecimod blocks the binding of superantigens from Gram-positive pathogens to CD28 and impairs endotoxin-mediated activation of T cells in Gram-negative bacterial infections[56]. AB103 was demonstrated to reduce mortality in mouse models of polymicrobial and Gram-negative bacterial infections[54,57]. A clinical trial has also shown the good safety profiles of a single intravenous dose of AB103 at 0.25 mg/kg or 0.50 mg/kg[58]. Moreover, a Phase III clinical trial has been completed and demonstrated that early treatment of reltecimod in severe necrotizing soft tissue infections resulted in a significant

improvement in the primary necrotizing infection according to the clinical composite endpoint[59]. The primary endpoint, which used Necrotizing Infection Clinical Composite Endpoint that required patients to meet all components of the composite score, was 54.3% vs. 40.3% for reltecimod and placebo, and was associated with improved resolution of organ dysfunction (70.9% vs. 53.4% for reltecimod and placebo) and hospital discharge[59].

Murepavadin, an antimicrobial peptidomimetic developed by Polyphor Ltd., binds to the lipopolysaccharide transport protein D (LptD), inhibiting the transportation and location of lipopolysaccharide and disrupting the cell membrane integrity, leading to cell death[60,61]. It was initially designed and synthesized based on the membranolytic host-defense peptide protegrin I, after which iterative cycles of peptidomimetic library synthesis and screening were performed to improve its antimicrobial activity[61]. It belongs to the class of outer membrane protein targeting antibiotics, which are fully synthetic compounds[62], and exhibit a specific and potent activity against *P. aeruginosa* *in vitro* and in biofilms[63,64]. A pharmacokinetics and safety study showed that murepavadin was well tolerated in individuals with a range of renal function (from normal, mild to severe renal function impairment); dose adjustment was warranted in renal dysfunction patients[65]. In a completed Phase II clinical trial, 12 patients with *P. aeruginosa* ventilator-associated pneumonia infections received murepavadin treatment, and 10 (83%) of these patients achieved a clinical cure. The 28-day all-cause mortality rate was 8%, which was far below the 20%–40% expected mortality rate[60]. However, the Phase III clinical trials for treating nosocomial pneumonia or ventilator-associated pneumonia caused by *P. aeruginosa* have been terminated due to higher-than-expected kidney injury incidences.


### AI in antimicrobial development

As the scale of biological big data continues to increase, a variety of AI methods for analyzing biological big data have emerged[66]. AI technology can enable computers to learn and improve automatically without explicit programming, and construct and predict models using data. The methodology domain involved in AI mainly includes reasoning, knowledge representation, search for solutions and machine learning (ML)[67]. Deep learning (DL), a constituent of ML, involves a neural network that mimics the structure of the brain and is used to recognize and differentiate patterns of language, images, videos, and various biological data types[68,69]. DL-related algorithms have advanced rapidly in recent years, and several typical algorithms, including convolutional neural

networks, recurrent neural networks, deep reinforcement learning, and particularly, generative adversarial networks, as an unsupervised learning algorithm[70], have been extensively applied in various fields of drug discovery[71-73].

AI technology constitutes a powerful tool to combat AMR[74-76]. For example, data-driven methods can be used to predict novel antibiotic compounds, while image-based methods can help identify resistant bacteria[77]. AI-assisted compound library screening or new compound structure design can help quickly identify more promising

antimicrobial compounds. In addition, AI can leverage known data, such as genomic data, to predict potential resistance sites and related enzymatic functions, laying the groundwork for designing better antibiotics[78]. Furthermore, AI has facilitated target identification and dynamic modeling, peptide design and synthesis, evaluation of SAR and STR, and drug repurposing[79] (Fig. 2). In the following sections, we will categorize antimicrobials into 4 major groups: small molecules, AMPs, phage therapy, and essential oils (EOs). We will also discuss the role of AI in the development of each category.



**Fig. 2 Artificial intelligence (AI) in small-molecule antibiotic development.**

AI-based methods empower novel small-molecule antibiotic discovery from multiple dimensions, including mining secondary metabolites encoded by biosynthetic gene clusters (BGCs), screening existing compound libraries, and repurposing the Food and Drug Administration (FDA)-approved drugs. AI-based prediction of protein structures and functions, such as AlphaFold2 and RoseTTAFold, remarkably expands the protein space for docking simulations and drug rational design

### AI in small-molecule antibiotic development

The screening of soil microbe-derived secondary metabolites exhibiting antibacterial properties was once the predominant method for identifying novel antibiotics, especially between the 1950s and 1960s, a period known as the golden era of antibiotic discovery[80]. Unfortunately, this approach's success was impeded by the rediscovery problem, and in later periods, a substantial majority of newly developed antibiotics achieving clinical utilization were classified as analogs of

existing antibiotic classes. The enduring efficacy of these analogs faced challenges due to the pervasive prevalence of existing resistance determinants[9]. Ideally, new antibiotic discovery should aim to pursue novel chemotypes with MOAs distinctly dissimilar from existing antibiotics. Such compounds are more likely to evade existing resistance determinants and therefore exhibit prolonged utility over time. Fortunately, AI technologies have been speeding up this process from multiple angles. In this section, we will discuss AI-facilitated small-

molecule antibiotic discovery from 4 aspects: identification of biosynthetic gene clusters (BGCs), compound library screening, protein structure-function-guided drug rational design, and drug repurposing (Fig. 2).

#### **Small molecule antibiotic development by BGCs**

BGCs serve as natural reservoirs encoding a plethora of secondary metabolites with the potential to become novel antibacterials[81]. However, tapping into the full potential of BGCs is hampered by the fact that many BGCs belong to organisms that cannot be cultured under laboratory conditions. Even for those that are culturable, BGCs could be cryptic or remain transcriptionally silent. Therefore, there is a strong demand for *in silico* prediction of BGCs through genome mining. Despite traditional rule-based systems such as antibiotics and secondary metabolite analysis shell (antiSMASH)[82] and Antibiotic Resistant Target Seeker (ARTS)[83] having already shown great success, AI has been playing an increasingly important role[81]. DeepBGC utilized a DL algorithm to uncover novel BGC classes and predict products' chemical activity[84]. Another DL-based method, DeepRiPP, integrated both genomic and metabolomic data for predicting ribosomally synthesized and posttranslationally modified peptides[85]. PRISM 4, on the other hand, achieved predictions using the sequence information of the BGC to predict the chemical structures of the secondary metabolites, from which the activities can be inferred[86]. Walker *et al.*[87] also accomplished highly accurate activity prediction by combining BGCs and profiles of resistance markers.

#### **MOA driven drug screening**

Conventional drug screening is limited by the size of the compound library and is often unable to determine the MOA of the hits. To overcome these limitations, Johnson *et al.*[88] developed a novel paradigm termed PROSPECT (primary screening of strains to prioritize expanded chemistry and targets) by performing a primary chemical screen on *Mycobacterium tuberculosis* (*M. tuberculosis*) hypomorphs (mutant strains depleted in essential targets). As a result, over 8.5 million chemical-genetic interaction profiles were generated, and with the help of supervised learning, a significantly increased number of inhibitors against essential targets such as DNA gyrase and folate metabolism were identified[88]. Moreover, ML-based screens enable the exploration of extensive chemical spaces *in silico*. This, in turn, substantially enhances the probability of unearthing structurally and functionally novel compounds imbued with potent antibacterial properties. Taking *A. baumannii*, a nosocomial pathogen notorious for drug resistance, as an example, Liu *et al.*[89] trained a message-passing deep neural

network with growth inhibition data from around 7500 FDA-approved compounds, which then discovered aubacin, a narrow-spectrum antibiotic with a novel MOA targeting lipoprotein trafficking.

#### **AI in protein structure prediction and drug design**

In addition to mining for novel secondary metabolites and screening existing compound libraries, AI-based approaches can also promote the rational design and optimization of drugs. The basis of rational design lies in understanding the three-dimensional structure, and in many cases, protein-protein interactions of the drug target. Although experimental determination remains the gold standard for protein structures, the process is low-throughput, and for many proteins, it remains technically challenging. Fortunately, this was revolutionized by the advent of the neural network AlphaFold2 by Deep-Mind, which achieved structure prediction for the majority of proteins with near-experimental accuracy[90,91]. Inspired by the principles of AlphaFold2, Baek *et al.*[92] created RoseTTAFold, a three-track neural network for structure prediction that achieved accuracy approaching that of AlphaFold2. RoseTTAFold also enables the prediction of protein-protein interactions directly from protein sequences, avoiding the need for subunit structure prediction and docking[92].

To apply these powerful tools for antibiotic discovery, Wong *et al.*[93] conducted molecular docking simulations using structures of the *E. coli* essential proteome predicted by AlphaFold2, along with hundreds of active/inactive antibacterials, and performed *in vitro* enzymatic assays to assess the model performance. Unfortunately, the model showed, on average, weak performance across 12 essential targets with an area under the receiver characteristic curve (AUROC) of 0.48, and this was attributed to the docking method rather than AlphaFold2 predictions[93]. To improve performance, a combination of ML-based scoring functions was employed to refine the docking calculations, leading to a significantly increased AUROC[93]. Overall, this indicates that there are still significant roadblocks to accurately predicting how drug candidates bind to their targets, even with the help of AlphaFold2, and improving ligand binding poses predicted by docking simulations to AlphaFold2 models holds the key[93,94].

Both AlphaFold2 and RoseTTAFold use multiple-sequence alignments as inputs for DL, sacrificing time for database searching for prediction accuracy. To overcome this limitation, Fang *et al.*[95] developed HelixFold-Single, an algorithm that combines a protein language model and geometric learning from AlphaFold2. Due to the avoidance of multiple-sequence

alignment, compared to AlphaFold2, HelixFold-Single reduces prediction time by 99.9% for proteins smaller than 100 amino acids and still by 96% for proteins larger than 800 amino acids, greatly facilitating applications such as high-throughput protein structure predictions[95].

With the success of AlphaFold2 and RoseTTAFold, the next significant question pertains to predicting the function of proteins directly from their primary sequence[96]. Answering this question could lead to a substantial expansion of potential targets for antibiotic discovery. Conventional alignment-based methods struggle to detect remote homology, and approximately one-third of bacterial proteins remain unannotated[97]. To address this gap, Gligorijević *et al.*[98] developed DeepFRI, a graph convolutional model consisting of a two-stage architecture that incorporates both protein structure and sequence represented in a long short-term memory language model. This allows DeepFRI to extract local sequence and global structure features, bypassing limitations imposed by homology-based function transfer. In addition, Mistry *et al.*[99] and Bileschi *et al.*[100] trained neural networks ProtCNN and ProtENN using curated seed sequences from Pfam. These models outperformed existing methods such as TPHHM and BLASTp[100]. Moreover, when combined with existing methods, DL models can learn complementary information and offer approximately 6.8 million new sequence region annotations, significantly expanding the coverage of Pfam by more than 9.5%[100].

Structural homology is more conserved and, hence, of greater value in predicting protein functions than sequence homology across long evolutionary distances. Based on this principle, Hamamsy *et al.*[101] developed a workflow consisting of two consecutive DL methods, TM-Vec and DeepBLAST. TM-Vec employs TM-scores as a metric to search for structural similarities in large sequence databases directly from sequence pairs without intermediate structural prediction. DeepBLAST then performs subsequent structural alignments. This workflow outperforms existing sequence-alignment methods for remote homology detection and ultimately expedites protein function prediction[101].

The concept of rational design goes beyond predicting protein structures and functions. Inspired by natural language processing (NLP), Mansbach *et al.*[102] took fragment-based representations and drug activity to train an ML algorithm termed "Hunting FOX". Unlike conventional fragment-based drug design approaches that rely on predefined fragments, Hunting FOX enables the extraction of all potential fragments from compounds to form hybrids with novel functionalities[102]. With Hunting FOX, Mansbach *et al.*[102]

identified a chemical vocabulary related to high permeation into *P. aeruginosa* and validated this approach *in vitro*.

There are also novel approaches to drug design and screening that involve entirely new structures and operate at a much faster pace than ever before. *De novo* drug design, a computational approach, designs new chemical structures from atomic building blocks without being restricted by SAR or drug-target interaction relationships. Deep reinforcement learning, which combines artificial neural networks (ANNs) with reinforcement-learning architectures, has been successfully employed for *de novo* drug design[103]. Monte Carlo tree search integrated with symbolic AI was applied to guide the selection of promising retrosynthetic steps and search for drug candidates. This approach was 30 times faster than the traditional computer-aided search method[104].

#### **AI in drug repurposing**

Drug repurposing, involving the identification of new applications for existing drugs, has been gaining momentum in both the public and private sectors, especially for diseases that are underserved due to the high costs and extended timeline associated with *de novo* drug development. With the assistance of AI, drug repurposing has witnessed significant breakthroughs in the fight against global pandemics and AMR[105,106]. A total of 4707 compounds, including 3422 marketed drugs, were collected in an online Drug Repurposing Hub[107]. Two steps were employed to identify drugs with repurposing potential. First, all the existing drugs were collected and integrated into a database. Second, all the chemicals that had reached clinical development were selected and subjected to structure-matching analysis. After clustering analysis, the compounds were clustered into different groups using a self-organizing map algorithm. Researchers from the Massachusetts Institute of Technology used ML-based AI to identify novel antibacterial molecules from the Drug Repurposing Hub[108]. For example, halicin, an anti-diabetic drug, has bactericidal effect by damaging the electrochemical gradient of the bacterial membrane[108]. From this conserved MOA, halicin was shown to display antimicrobial activity against a broad spectrum of pathogens, such as *M. tuberculosis*, carbapenem-resistant *Enterobacteriaceae*, *Clostridium difficile*, and *A. baumannii*[109]. Besides, the naive Bayesian approach combined with whole-cell screening identified 5 molecules from the GlaxoSmithKline antimalarial database with potent activity against *M. tuberculosis* activity, showing repurposing potential[110]. Furthermore, support vector machines and random forest methods were combined to construct an antibacterial compound predictor using chemicals with known antibacterial properties from the ChEMBL database[111].

The resulting predictor was then employed to screen FDA-approved small molecules from the DrugBank database, identifying 1087 compounds predicted to have potential antibacterial activities. Notably, among the 1087 compounds, 154 are already FDA-approved antibacterial drugs. Encouraged by this result, 8 compounds with novel structures were selected for further experimental validation[111]. These innovative approaches provide new insights for antibacterial discovery and will undoubtedly contribute to new antimicrobial development.


### AI in AMP discovery

AMPs are a class of structurally diverse small peptides based on their antimicrobial activities, typically containing a few to dozens of amino acid residues in their sequence, with or without further modifications, exerting their antimicrobial activities through a variety of mechanisms[112]. AMPs are proposed to target cell membranes, demonstrating the capability to bind and disrupt both negatively charged and

zwitterionic membranes, ultimately leading to membrane permeabilization. This specific MOA positions AMPs as a new class of potential antibacterial drugs, which likely makes it challenging to develop resistance[46,112].

### AMP mining from extant sequence space

Novel AMP development has also benefitted substantially from the involvement of AI[113] (Fig. 3). Platforms such as Deep-AmPEP30 (a DL-based platform)[114], IAMPE (a webserver with ML algorithms)[115], and DeepACP (a deep recurrent neural network-based model)[116] have greatly facilitated novel peptide discovery and synthesis. Besides, there are well-maintained databases of AMPs derived from genetic sequences[117]. For instance, the AMPer database aims to classify natural and novel AMPs (including 1045 mature peptides and 253 peptides) by using hidden Markov models[118]. ANTIMIC collects approximately 1700 AMPs from eukaryotes and prokaryotes, which serve as templates for designing novel AMPs[119]. In addition, synthetic peptide



**Fig. 3 Artificial intelligence (AI) in the development of antimicrobial peptides (AMPs).**

AMPs databases have laid a solid foundation for AI-based model training, including natural language processing and deep generative networks. AI models can then be used to mine a wide range of protein sequence space, including the extinct human proteome, while high-throughput methods like cell-free synthesis significantly accelerate the speed of validation of candidate AMPs

design has helped to unravel the underlying SARs. There are also advanced strategies employed for potential AMPs design. Firstly, AMPs can be modified based on known AMPs, aiming to generate peptides with greater antimicrobial activity and/or reduced toxicity[120]. Efforts to design and synthesize protein epitope mimetics (PEMs) often lead to novel AMPs. Various PEMs, like  $\beta$ -hairpin structures and above mentioned LptD binding peptide murepavadin, are designed based on PEMs[121]. Biophysically motivated modeling studies have also been applied to understand AMP activity and design AMPs. Examples of modeling strategies include Gibbs free energy perturbation, molecular dynamics simulations, as well as thermodynamics calculations of the interactions between AMPs and cell membranes[122]. Bactenecin[122] and an indolicidin analog CP-11[123] are examples whose activities were studied and designed through this approach, respectively. In addition, Wu *et al.*[124] employed an amino acid-based activity prediction method that resulted in the identification of DP7. Compared to its parent peptide HH2, DP7 exhibits improved activity against *S. aureus* and lower cytotoxicity.

NLP is a type of DL that applies computer technology to the analysis and synthesis of natural language and speech[125]. Ma *et al.*[126] created a prediction method for AMPs by integrating 3 NLP neural network models—Long short-term memory, Attention, and Bidirectional Encoder Representations from Transformer. After learning from thousands of existing AMP sequences, they achieved a precision rate exceeding 90%, which is superior to previous models based on amino acid composition and properties for determining AMPs. Based on 2349 peptide sequences identified in human gut microbiome data as candidate AMPs, 216 synthetic AMPs were designed, and 181 were confirmed to have antimicrobial activity. Finally, 11 of these AMPs showed highly potent efficacy against multidrug-resistant Gram-negative bacteria[126]. This study showed the great potential of combining ML and large meta datasets, such as omics datasets, to improve the efficiency of AMP prediction and identify AMP molecules with new MOAs. By combining microbiome big data and the latest DL models, this study sets an excellent example of AI+microbiome molecular mining and transformation, showcasing the high feasibility of using computational methods to discover active molecules (such as proteins or RNA) for therapy from other types of omics data.

#### **AMP mining from extinct and virtual sequence space**

Microbes are not the sole source for AMP mining. Based on the concept of “molecular de-extinction”, Maasch *et al.*[127] developed panCleave, a random forest model capable of predicting proteome-wide cleavage sites to prospect

for AMPs encrypted within extinct and extant human proteomes. Lead AMPs identified by panCleave exhibited membrane permeabilization and anti-infective efficacy against *A. baumannii* in both murine skin abscess and thigh infection models, highlighting the potential of paleoproteome as a reservoir for drug candidates[127]. AMP mining from existing proteomes, regardless of the source, is inevitably biased towards the sequence space confined by the proteome. To explore the entire space of peptide sequences, Huang *et al.*[128] developed a sequential model ensemble pipeline comprised of ML modules with a coarse-to-fine design principle to mine the entire virtual library of peptides with length of 6-to-9 amino acids. Three lead hexapeptides identified by this pipeline exhibit potent activity against multidrug-resistant clinical isolates in both *in vitro* and *in vivo* models, indicating the great potential of sequential model ensemble pipeline for unbiased peptide screening tasks[128].

#### **De novo design of AMP**

AMPs have also been designed *de novo* through deep generative neural networks[129]. Researchers from International Business Machines Corporation employed two types of variational inference autoencoder[129]: the classic Variational Autoencoder (VAE) and the Wasserstein Autoencoder, to design two novel and highly active AMPs[130]. In this study, the peptide generation problem is represented as a density modeling mathematical problem; the model samples the peptide sequence space in a way that primarily involves the regions with high probability density. The density estimation algorithm has been adjusted to assign high likelihoods to known peptides and “punish” random meaningless sequences[130]. Additionally, the researchers used 1.7 million peptide sequences from the UniProt database to train the algorithm. The contact frequency between positive residues and lipid bilayers was used as a predictive metric for antimicrobial activity[130]. After high-throughput *in silico* screening, only 20 peptide sequences were retained. They were transferred to wet laboratories for characterization of their antimicrobial activities against model bacterial strains, including Gram-positive *S. aureus* and Gram-negative *E. coli*. Within just 48 d, two novel AMPs with broad-spectrum antimicrobial activity were discovered[130]. Another endeavor to design AMPs using a deep generative model was achieved by Szymczak *et al.*[131] who proposed HydrAMP, a conditional VAE that performs both analog generation and unconstrained generation. The AMPs showed potent activities against 5 bacterial strains (both Gram-positive and Gram-negative) including those that are antibiotic-resistant. This demonstrates that HydrAMP represents a remarkable advancement in

designing novel AMPs with high potency to combat antibiotic resistance[131].

One consequence of the *de novo* design of AMPs through deep generative neural networks is the large cohort of candidate peptides for *in vitro* validation. Compared to chemical synthesis, DNA-based bioproduction significantly increases the throughput for peptide screening, but cell-based methods are limited due to the toxicity of peptides to their bacterial chassis[132]. To address this limitation, Pandi *et al.*[132] developed a cell-free protein synthesis pipeline to test 500 DL-based *de novo* designed AMPs, from which 6 AMPs displayed broad-spectrum activity against multidrug-resistant bacterial isolates, indicating the power of DL-based design and cell-free protein synthesis in AMP development.


#### AI in phage therapy development

In addition to small-molecule agents and AMPs, alternative strategies have also played vital roles in the battle against antibiotic resistance, one of them being phage therapy[133,134]. Bacteriophages, natural predators of

bacteria, have co-evolved with their bacterial hosts for 3.8 billion years and form an integral part of the human microbiome[135]. Compared to antibiotics, which are mostly broad-spectrum, phage therapy offers remarkably higher specificity, minimizing disturbances to the microbiota and preventing antibiotic-induced AMR dissemination[136,137]. There have already been several examples of clinical success[138-141]. This section delineates the rational design of phage therapy into 4 consecutive steps: phage identification, prediction of phage virion proteins (PVPs), analysis of phage lifestyle, and exploration of phage-host interactions, providing a review of the contribution of AI in each stage (Fig. 4).

#### Phage identification

Recent advances in metagenomic sequencing have highlighted the pivotal role of viruses in various ecosystems[142]. To address this growing significance, innovative AI-driven tools have been developed for the discovery, annotation, and analysis of viral sequences within complex metagenomic datasets[143,144]. Seeker, for instance, is a DL-based tool



**Fig. 4 Artificial intelligence (AI) in the development of phage therapies.**

AI-based models have played a significant role in studying phages from their natural sources. This includes identifying phages from metagenomic samples, annotating phage virion proteins from phage genome sequences, predicting phage hosts, and determining phage lifestyles. These efforts lay a solid foundation for developing novel phage therapies

that swiftly detects diverse bacteriophages, even in cases where they exhibit minimal sequence similarity to known phage families[145]. Meanwhile, VIBRANT employs a hybrid ML and protein similarity approach to autonomously recover, annotate, and assess the metabolic impacts of viruses in metagenomic assemblies, surpassing traditional virus identification programs[146]. In addition, VirSorter2 significantly enhances the accuracy and breadth of virus sequence detection in metagenomic datasets, utilizing multiple classifiers to detect a wide range of viruses with high precision[147]. Moreover, PhageBoost, a novel ML method based on feature space designed for fast and generalized prophage discovery, significantly enhances bacteriophage identification[148]. DEPhT is a multimodal tool tailored for the discovery, precise extraction, and annotation of prophages in *Mycobacterium* genomes, enabling detailed comparative genomic analyses through efficient discrimination between phage and bacterial sequences[149]. Furthermore, Phanta excels in virome-inclusive gut microbiome profiling, relying on K-mer-based classification methods and comprehensive gut viral genome catalogs to quickly and accurately quantify both prokaryotes and viruses, significantly improving viral species identification compared to assembly-based methods[150].

#### **PVPs prediction**

PVPs, encompassing capsid proteins, tail proteins, and phage particle enzymes, play a critical role in governing bacteriophage and interactions with their bacterial hosts[143]. Predicting PVPs is crucial as it enables the functional annotation of these proteins, improving our understanding of their potential utility in phage therapy, such as shelf-life, particularly valuable when a significant percentage of these proteins lack assigned functions due to low sequence conservation and limited experimental data.

To address this demand, multiple AI-driven initiatives have emerged. In an early pioneering effort, Seguritan *et al.*[151] developed ANNs to predict phage structural protein sequences, enabling the identification of virion structures even in the absence of significant similarities to known sequences. Subsequently, phage artificial neural networks (PhANNs) were introduced, employing an ensemble of ANNs to categorize phage open reading frames into 10 major structural protein classes or “other” category, delivering swift and precise functional annotations for diverse phage sequences[152]. In addition, STEP3 is a computational tool that harnesses evolutionary features in diverse phage genomes to achieve robust and accurate predictions, addressing the challenge of poor genome annotation and improving the quality of phage cocktails for more effective phage therapy[153]. Moreover,

SCORPION employs a two-step feature selection strategy to construct a feature vector and build a stacked model, offering a cost-effective and scalable tool for the accurate identification of PVPs solely based on protein primary sequences[154].

#### **Phage host prediction**

The identification of host organisms for phages is of paramount importance in understanding viral-host relationships and advancing therapeutic applications. To address this challenge, innovative computational methods have been developed. VirHostMatcher-Net employs a flexible network-based framework, integrating CRISPR sequences and alignment-free similarity measures, which significantly improves host prediction accuracy and greatly expands the spectrum of known virus-host interactions[155]. Meanwhile, the development of a computational model based on genome analysis enables efficient prediction of phage-bacterium interactions, achieving a predictive performance of around 90%[156]. Furthermore, HostG, a semi-supervised learning model, leverages a knowledge graph and graph convolutional network to enhance host prediction for novel viruses, offering the valuable ability to predict hosts from new taxa[157]. These approaches collectively contribute to our ability to decipher viral-host relationships and explore the potential applications of bacteriophages in various domains.

#### **Phage lifestyle prediction**

Bacteriophages exhibit two contrasting lifestyles: virulent and temperate, with the virulent lifestyle bearing significant implications for phage therapy. The prediction of phage lifestyles is crucial but remains challenging, especially for phages constructed from metagenomic data. To address this issue, innovative AI-driven approaches have emerged. PHACTS (Phage Classification Tool Set) introduces a novel similarity algorithm and a supervised random forest classifier to accurately classify phages into virulent or temperate categories, achieving an impressive precision rate of 99%[158]. In parallel, BACPHLIP (BACTERioPHage Lifestyle Predictor) employs conserved protein domains and a random forest classifier to predict the lifestyle of bacteriophages, attaining an outstanding accuracy of 98%[159]. Moreover, by harnessing Bidirectional Encoder Representations from Transformer, a contextualized embedding model inspired by NLP, to represent phage contigs, PhaTYP (Phage TYPE prediction tool) achieves outstanding performance in accurately predicting the lifestyles of phages from short contigs[160].

#### **AI in the discovery of antibacterial EOs**

Another important class of non-traditional antibacterial agents is EOs. The antibacterial mechanism of EOs is complex, and various mechanisms have been proposed. The most common


mechanism is that they penetrate through the cell wall and membrane, ultimately disrupting cell membrane integrity and causing cell death[161]. It has been also proposed that EOs can destabilize cellular architecture, affect the external envelope of the cell, and reduce membrane potential[162]. Predicting EOs' bioactivities is challenging due to prevalent synergisms and antagonisms between EOs' complex components. Thus, time-consuming disk diffusion assays are required for each new combination. ANNs were trained to predict the antimicrobial activity of EOs and extract fractions against 4 main pathogens (*S. aureus*, *E. coli*, *Candida albicans* and *Clostridium perfringens*) [163]. Notably, the ANN reached >70% prediction accuracy within a 10 mm maximum error range, making it a reliable and fast tool for predicting the antimicrobial activities of EOs[163].

**AI in predicting MOA and resistance mechanisms of novel antibacterials**

**Public databases for resistance development prediction**

Resistance development is an inevitable consequence of any

antibacterials and its mechanism is strongly linked to the MOA of the cognate drug. Therefore, it is essential to track, monitor and predict bacterial genome evolution, mutation developments and resistant genes epidemiology. ML-based approaches have been applied to mine bacterial genomic data to decipher resistance mechanisms and predict resistance development (Fig. 5). This is crucial for decision-making when developing drug candidates in advance of resistance development. BacMet (<http://bacmet.biomedicine.gu.se>) is a bacterial resistance gene database that has collected 753 bacterial resistance genes confirmed by experiments, and it contains 155,512 potential predicted resistance genes based on sequence similarity of the experimental-confirmed genes[164]. The Comprehensive Antibiotic Resistance Database (<https://card.mcmaster.ca/>) is a curated bioinformatic database of resistance genes, their products, and associated phenotypes. It includes 6627 ontology terms, 5010 reference sequences, 1933 single nucleotide polymorphisms, 3004 publications, and



**Fig. 5 Artificial intelligence (AI) in deciphering the mechanisms of action (MOA) and resistance mechanisms of novel antibacterials.**

Comparing cellular responses of bacteria before and after treatment of an antibacterial compound through multidimensional profiling enables AI-based methods to delineate the MOA of compounds and predict mechanisms of arising resistance. AMR. Antimicrobial resistance

5057 AMR detection models[165]. Comprehensive Antibiotic Resistance Database also provides predicted resistomes for 377 important pathogens including 21,079 chromosomes, 2662 genomic islands, 41,828 plasmids, 155,606 whole-genome sequencing assemblies, and 322,710 alleles (data released in July 2022). The Bacterial Diversity Metadatabase (<https://bacdiv.dsmz.de/about>) is currently the largest database with standardized bacterial phenotypic information, containing 81,827 bacterial and archaeal strains, including 14,091 strains which covers approximately 90% of species[166]. Furthermore, libraries such as Plasmid ATLAS[167], and Virulence Factor Database[168] provide solid support for predictions against plasmid-borne genetic factors and virulence factors, respectively.

#### **AI in phenotype-assisted prediction of resistant determinants**

Publicly available databases alone do not provide a complete solution; traditional approaches relying on searching for known resistant determinants in existing databases are intrinsically biased towards known antibiotic-resistance genes (ARGs), resulting in high false negative rates[169]. To overcome such limitations, bacterial genome sequences and antimicrobial susceptibility testing (AST) metadata have been exploited to train various ML-models[170], enabling downstream prediction tasks[171]. For instance, PATRIC (<http://patricbrc.org/>) is a database capable of predicting phenotypes and identifying of genomic regions relating to resistance[172]. Building on PATRIC, AdaBoost ML classifiers were built to identify carbapenem resistance in *A. baumannii*, methicillin-resistant *S. aureus*, and  $\beta$ -lactam resistance in *K. pneumoniae*, utilizing wholegenome bacterial data and MICs[173]. Later, Moradigaravand *et al.*[169] demonstrated that the gradient boosted decisions tree model stood out as the best ML model for predictions the resistance of *E. coli* against eleven compounds across 4 major antibiotic classes.

Moreover, Her *et al.*[174] took a pan-genome-based approach and found that AMR genes are unevenly distributed in the core and accessory genomes. Dividing the pan-genome into core and accessory parts further improved prediction accuracy in *E. coli*. Large and high-quality training sets enable ML models to reach even higher predictive power. Nguyen *et al.*[175] also employed an extreme gradient boosting (XGboost)-based ML model, achieving prediction not only for resistance but also for MIC in nontyphoidal *Salmonella*. Furthermore, the integration of transcriptomes and genomes could further enhance the predictive powers of ML-based classifiers to predict AMR phenotypes in Gram-negative ESKAPE pathogens. A pioneering work by Bhattacharyya *et al.*[176] exploited differences in early transcriptional

changes between sensitive and resistant strains upon antibiotic treatments to train an ML classifier, resulting in GoPhAST-R, a rapid assay with high classifying accuracy on *E. coli*, *K. pneumoniae*, and *A. baumannii*. Following this, Khaledi *et al.*[177] took a similar approach by integrating single nucleotide polymorphisms, gene presence/absence and transcriptomic profiles measured in unstressed conditions, obtaining an ML model with high predictive value and sensitivity on *P. aeruginosa*.

In addition to predicting the resistance phenotype of individual strains, ML-based approaches have also been used to interrogate metagenomic data. Deep-ARG, a DL-based model built on a dissimilarity matrix created from all known categories of ARGs, demonstrates both high precision and recall[178]. DeepARG has two versions: SS and LS, tailored to handle short and long sequence reads from metagenomic libraries, respectively[178]. Moreover, using an ML-based approach, it was found that genes such as subclass  $\beta$ -lactamases and vancomycin resistance regulators play a crucial role in determining the bacterial survival upon antibiotic treatment in premature infant gut microbiome[179].

Interpretation of ML models could go beyond resistance prediction and even offer mechanistic insights. An ML model trained using genome sequences of *K. pneumoniae* exhibiting polymyxin resistance (PR) identified not only known PR genes but also several stress response genes as potential novel PR determinants[180]. This theme was recapitulated by Sunuwar *et al.*[181] who invented a bioinformatics framework to predict loci underlying AMR phenotypes.

#### **AI in functional annotation of antibacterials through integrated profiling**

Adaptation of bacteria to antibiotics is a complex process, often involving systematic alterations of cellular pathways at multiple levels. Therefore, in addition to the traditional view where drug-target interactions are the major focus, a more holistic perspective is required to provide deeper insights into bacterial resistance development and evolution. Fortunately, the advances in molecular measurement technologies enable multi-dimensional profiling of features of bacteria upon drug treatments, including both macroscopic cell morphology and microscopic omics (genome, transcriptome, proteome and metabolome) characteristics[182]. Moreover, when such profiling is integrated with compound library screening and genome editing technologies, it has enabled the coupling of physicochemical properties of compounds with their phenotypic and molecular downstream impacts, revealing MOAs and resistant mechanisms of compound libraries[182].

The high dimensional and heterogeneous nature of drug

profiling data types inevitably brings new challenges in data processing and interpretation, making ML algorithms particularly efficient tools for data mining[183]. In the following section, specific examples of coupling of drug multi-dimensional profiling and ML classifier models from multiple levels will be discussed.

At the level of cell morphology, bacterial cytological profiling is a fluorescence microscopy-based method capable of identifying cellular targets of antibacterial compounds with high distinguishing power and throughput[184]. The development of DL-based image processing algorithms, such as resolution enhancement[185], has led to the creation of platforms like MorphEUS, designed to classify drugs against *M. tuberculosis*[186]. In some cases, bacterial cytological profiling fails to classify a compound in any existing MOA class, such as in the case of SCH-79797; however, it often suggests a novel MOA[187]. Further characterization combining genetic, proteomic, metabolomic, and cell-based assays, demonstrated that SCH-79797 is a dual-mechanism drug targeting both folate metabolism and membrane integrity[187].

At the transcriptome level, by integrating the growth responses to different drug combinations, transcriptome profiling to single drugs, and transcription factor regulatory networks of *M. tuberculosis*, Ma et al.[188] developed INDIGO-MTB, an ML-based classifier capable of predicting drug synergy for treating *M. tuberculosis* infections. Additionally, it identified Rv1353c as a transcription factor regulating multiple drug interactions.

At the level of proteome, Weis et al.[189] combined ML algorithms and MALDI-TOF mass spectrometry to yield substantial acceleration of AMR determination. They collected mass spectrometry data from clinical strains using Bruker's MALDI Biotyper microbial mass spectrometry system and coupled this data with strains' resistance profiles to create the DRIAMS dataset[189]. The dataset includes 768,300 pieces of resistance data for more than 70 antimicrobials and MALDI-TOF mass spectrometry data for more than 300,000 clinical strains of 803 pathogens. They used datasets to train three ML algorithms: logistic regression, a deep neural network classifier (multilayer perceptron, MLP), and gradient-boosted decision trees (LightGBM). Applying AUROC as the performance metric, MLP and LightGBM were demonstrated to be the best-performing classifiers[189]. Therefore, this new approach is anticipated to be a dependable and efficient way to improve antibiotic stewardship and optimize infection treatment regimens in the future.

At the level of metabolome, using the metabolic responses of *Mycobacterium smegmatis* to 62 reference compounds

with known MOAs, Zampieri et al.[190] established a drug-metabolome profile compendium that was used to predict the MOAs of 212 novel antimycobacterial compounds. This approach managed to predict the MOAs of 77% of novel compounds, some of which were experimentally validated[190]. To further explore phenotypic space potentially unreachable by existing reference compounds, Anglada-Girotto et al.[191] exploited CRISPR interference (CRISPRi) technology to systemically knockdown 352 essential genes in *E. coli* and combined it with non-targeted metabolomics to generate a reference map of metabolic changes. When compared with 1342 drug-induced metabolic changes, this integrated approach succeeded in high-throughput *de novo* functional annotations of novel antibacterials[191].

In contrast to conventional ML techniques, which explore and extract information from large omics or systematic datasets to understand relationships between antibiotic treatments and cellular phenotypes but create "black-boxes" where only correlative relationships are identified, the "white-boxes" approach, based on genome-scale metabolic network model (GSMM), was reported to establish causal relationships that aid mechanistic interpretation[192]. GSMM integrates both experimental (incorporating transcriptomic, proteomic, and biochemical screening) and computational modeling (network modeling and ML) to form an ML approach to reveal the MOAs of antibiotics[192]. Through these models, complicated cellular responses are integrated, and key metabolic pathways are extracted by constraint-based methods. Yang et al.[192] constructed a GSMM and demonstrated that purine biosynthesis pathway, central carbon metabolism, and redox status are crucial pathways for bacterial survival to antibiotics. CarveMe is an open-source, user-friendly automated tool designed to construct GSMM of bacterial species. It employs a top-down approach that begins with building a universal single-species model and then incorporates manually curated models to reproduce experimental phenotypes[193]. Currently, CarveMe has created a database of 5587 bacterial models for users to apply and understand the key cellular responses to antibiotics.

#### **AI in antibiotic stewardship**

Antibiotic misuse is a strong driving force for the emergence and exacerbation of AMR. Accurate prescriptions should be based on the AST results of the infecting pathogen, but standard AST takes days. Therefore, in practical terms, the demand for rapid clinical intervention often necessitates empirical drug prescriptions in the absence of AST data, posing the risk of ineffective treatment and AMR development[194].

Advanced molecular profiling methods, such as those discussed in Sect. 2.5, inevitably require powerful equipment and technical expertise and hence are still at the laboratory stage. Therefore, the clinical demand for a rapid, accessible way of predicting bacterial antimicrobial susceptibilities to guide prescription is significant, and AI has again been deeply involved to meet it[195].

By examining a 10-year longitudinal data set encompassing 711,099 community-acquired UTIs from 315,047 patients, Yelin *et al.*[196] found strong correlations between antibiotic resistance and parameters obtained from the clinical history of patients. The integration of those correlations gave rise to ML algorithms capable of predicting drug-specific antibiotic resistance in a personalized fashion, and a 1-year retrospective testing demonstrated that the ML algorithms significantly reduced the rate of mismatched treatment from over 8% to below 6%[196]. In addition, Kanjilal *et al.*[197] developed an ML decision algorithm using electronic health record data from over 10,000 patients with uncomplicated UTIs from 2007–2013 in Boston to recommend the narrowest possible antibiotic. When evaluated on a test cohort of 3629 patients retrospectively, compared to clinicians, this algorithm achieved a 67% reduction in the use of second-line antibiotics[197]. Similar endeavors to exploit ML to personalize antibiotic selection were done in the UK and Greece[198,199].

ML goes beyond merely reducing the rate of mismatched treatments; it extends its capabilities to prevent post-treatment resistance-gaining bacterial recurrences[200]. Combining whole-genome sequencing and ML analysis of a large-scale longitudinal database of urinary and wound clinical isolates

pre- and post-treatment from the same patient, Stracy *et al.*[201] found that treatment-induced resistance emergence is largely caused by re-infection of a different resistant clone rather than *de novo* resistance evolution. Moreover, as a recurrence-causing resistant clone most frequently comes from a patient’s microbiota[202], it is in many cases reflected by the patient’s infection history, which could be analyzed by ML algorithms to offer personalized treatment recommendations to reduce the risks of treatment-induced AMR[201].

### Conclusions and future perspectives

In conclusion, despite AMR posing a serious threat to human health and having garnered extensive attention, the development of antimicrobials has been slow. Only 18 novel antibiotics were approved from 2014 to 2021, with only 2 possessing a novel MOA. By analyzing antibiotics currently in clinical development, it has been revealed that novel antibiotic development is showing two trends: 1) from synthetic small molecules to biologicals; and 2) from broad spectrum to narrow spectrum. To meet everpressing clinical demands, AI has already been involved in the discovery of novel AMPs and EOs, drug repurposing, and resistance mechanism prediction (Table 2).

In the future, AI is likely to be involved in more stages of drug development, including molecular design, prediction of dosage regimens and associated effectiveness, dynamic modeling of protein-protein interactions[203], ligand-based simulation, quantitative structure-activity relationship modeling, molecular representations and high-order feature extraction[204], drug repurposing, and reduction of toxicity.

**Table 2 Antimicrobial drugs whose development has utilized computational and artificial intelligence (AI) technologies**

| Antibacterial drugs        | Development stage    | Technology  | Targeted pathogens   |
|----------------------------|----------------------|---|--|
| SPR206                     | Completed Phase I    | SAR-based design  | CRAB, CRPA, CRKP   |
| QPX 9003                   | Phase I              | SAR combining with STR and SPR-based design               | CRAB, CRPA, CRKP   |
| MRX-8                      | Phase I              | Soft drug design  | CRAB, CRPA, CRKP   |
| IB-367 (iseganan)          | Failed in Phase III  | Molecular dynamics simulation                             | Gram-negative and -positive pathogens and <i>Candida albicans</i>                |
| Reltecimod (AB103)         | Phase III            | Molecular dynamics simulation, binds to the CD28 receptor | Modulate the host’s immune response in severe Gram-negative bacterial infections |
| Murepavadin                | Terminated Phase III | Protein epitope mimetics                                  | CRPA   |
| Bactenecin                 | Preclinical          | Machine-learning classifier                               | <i>P. aeruginosa</i>   |
| Indolicidin analogue CP-11 | Preclinical          | Biophysically motivated modeling                          | Gram-negative and -positive pathogens, fungi, and viruses                        |
| Halicin                    | Preclinical          | Drug repurposing Hub                                      | <i>M. tuberculosis</i> , <i>C. difficile</i> , <i>A. baumannii</i> , and CRE     |

CRAB. Carbapenem-resistant *A. baumannii*; CRPA. Carbapenem-resistant *P. aeruginosa*; CRKP. Carbapenem-resistant *Klebsiella pneumoniae*; CRE. Carbapenem-resistant *Enterobacteriaceae*; SAR. Structure-activity relationships; STR. Structure-toxicity relationship; SPR. Structure-pharmacokinetic relationship; *P. aeruginosa*. *Pseudomonas aeruginosa*; *M. tuberculosis*. *Mycobacterium tuberculosis*; *C. difficile*. *Clostridioides difficile*; *A. baumannii*. *Acinetobacter baumannii*

With the substantial advantages of AI, potent chemical entities can be investigated at an unprecedentedly rapid pace compared to traditional methods, ultimately reducing drug development costs for research and development. This has the promise of increasing the success rate of clinical trials. The rapid advances of AI, combined with the current big data era (large datasets from high-throughput technologies, genomic/expression databases), should accelerate the emergence of new chemical entities possessing novel MOAs. As a result, more antibiotics or antibacterial biologicals are expected to make it through the drug development pipeline and enter the market. With the hope of combining new drugs and antibiotic stewardship, the fight against resistant bacteria should significantly benefit from the slower development of antibiotic resistance.

Furthermore, despite their high predictive performance, most current AI systems, particularly those that rely on deep neural networks, still suffer from several limitations. Firstly, DL can be prone to failures due to shortcut learning, namely decision rules that excel in standard benchmarks but struggle to adapt when tested under more demanding conditions[205]. This phenomenon often occurs in the later stages of tasks like drug design, which limits their use in decision-making[206]. The likelihood of failure can be reduced by calculating forecast uncertainty to prevent making poor decisions. Moreover, the model's decision-making can be examined and its reliability increased by expert supervision[207]. Secondly, a large proportion of existing AI models remain “black-boxes” models with low interpretability, meaning that humans cannot comprehend the rules behind decisions made[208]. This lack of transparency and accountability can lead to severe consequences, especially when it comes to high-stake decisions such as drug recommendations[208]. Therefore, despite the great challenges ahead, the direction toward more explainable AI is inevitable[209]. Thirdly, data availability is the key. AI has significantly shortened the *in vitro* stages in the drug-discovery pipelines of novel antimicrobials. However, little aid has been gained from AI regarding how those drugs behave in the human body, especially for biologicals due to their complex nature. The available data required to train AI models to address questions *in vivo* is far from sufficient[210]. To address this issue, it is crucial to strike a balance between data accessibility and confidentiality. Several promising avenues worth further exploration include federated learning, active learning, and swarm learning[210,211].

For any AI-based antimicrobial research, one can never overstate the importance of high-quality wet experimental data[207]. A future challenge will be the integration of drug discovery with disease progression, biomarker discovery, and

precision medicine. With the advances in high-throughput and single-cell technologies[212,213], AI could help build systematic models to rapidly diagnose diseases and automatically recommend more personalized treatments for patients. It could also encourage pharmaceutical companies to transition from biomarker discovery to drug development, revolutionizing future drug discovery and clinical practice[214].

AMR, due to the inappropriate overuse of antimicrobials, represents a complex challenge that extends beyond the development of new drugs and therapeutics. Resolving this problem, also requires a collaborative and integrated educational approach to the proper use of antibiotics by healthcare professionals and the public.

### Abbreviations

*A. baumannii*: *Acinetobacter baumannii*; AI: Artificial intelligence; AMPs: Antimicrobial peptides; AMR: Antimicrobial resistance; ANNs: Artificial neural networks; BGCs: Biosynthetic gene clusters; DL: Deep learning; *E. coli*; *Escherichia coli*; EOs: Essential oils; FDA: Food and Drug Administration; GSMM: Genome-scale metabolic network model; *K. pneumoniae*: *Klebsiella pneumoniae*; LptD: Lipopolysaccharide transport protein D; *M. tuberculosis*: *Mycobacterium tuberculosis*; ML: Machine learning; MOA: Mechanisms of action; NLP: Natural language processing; *P. aeruginosa*: *Pseudomonas aeruginosa*; PEMs: Protein epitope mimetics; PVPs: Phage virion proteins; PR: Polymyxin resistance; *S. aureus*: *Staphylococcus aureus*; SAR: Structure-activity relationships; SPR: Structure-pharmacokinetic relationship; STR: Structure-toxicity relationship; UTIs: Urinary tract infections; WHO: World Health Organization.

### Acknowledgements

Not applicable.

### Authors' contributions

GYL, DY, CT, and XFL conceptualized the theme of the review. GYL, DY, MMF, XZ, ZYJ, and XFL gathered relevant literature, and wrote the manuscript. GYL, CT, and XFL acquired the funding and revised the manuscript. All authors read and approved the final manuscript.

### Funding

This work was supported by the National Natural Science Foundation of China (32300157), the Shanghai Municipal Science and Technology Commission (19411964900), the Major Research and Development Project of Innovative Drugs, Ministry of Science and Technology of China (2017ZX09304005), and the Wellcome Trust.

### Availability of data and materials

Not applicable.

### Declarations

#### Ethics approval and consent to participate

Not applicable.

#### Consent for publication

Not applicable.

## Competing interests

The authors declare no interests of conflicts.

## Author details

<sup>1</sup>Department of Immunology and Pathogen Biology, School of Basic Medical Sciences, Hangzhou Normal University, Key Laboratory of Aging and Cancer Biology of Zhejiang Province, Key Laboratory of Inflammation and Immunoregulation of Hangzhou, Hangzhou Normal University, Hangzhou 311121, China. <sup>2</sup>National Key Discipline of Pediatrics Key Laboratory of Major Diseases in Children Ministry of Education, Laboratory of Dermatology, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China. <sup>3</sup>Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN 55905, USA. <sup>4</sup>Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA. <sup>5</sup>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA. <sup>6</sup>Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK. <sup>7</sup>Institute of Antibiotics, Huashan Hospital, Fudan University, Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of the People's Republic of China, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China.

## References

1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*. 2022;399(10325):629–55.
2. World Health Organization. A financial model for an impact investment fund for the development of antibacterial treatments and diagnostics: a user guide. 2020. Available from: <https://www.who.int/publications/i/item/a-financial-model-for-an-impact-investment-fund-for-the-development-of-antibacterial-treatments-and-diagnostics-a-user-guide>. Accessed 1 Jun 2020.
3. Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the United States, 2013. Atlanta, GA: US Department of Health and Human Services. 2013. Available from: <https://stacks.cdc.gov/view/cdc/20705>.
4. CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: US Department of Health and Human Services. 2019. Available from: <https://www.cdc.gov/drugresistance/pdf/threats-report/2019-arthreats-report-508.pdf>.
5. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. Review on antimicrobial resistance. 2016.
6. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. *Expert Rev Anti Infect Ther*. 2013;11(3):297–308.
7. Hu F, Wang M, Zhu D, Wang F. CHINET efforts to control antimicrobial resistance in China. *J Glob Antimicrob Resist*. 2020;21:76–7.
8. Ventola CL. The antibiotic resistance crisis, part 1: causes and threats. *PT*. 2015;40(4):277–83.
9. Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. *Curr Opin Microbiol*. 2019;51:72–80.
10. Katz L, Baltz RH. Natural product discovery: past, present, and future. *J Ind Microbiol Biotechnol*. 2016;43(2–3):155–76.
11. Greener JG, Kandathil SM, Moffat L, Jones DT. A guide to machine learning for biologists. *Nat Rev Mol Cell Biol*. 2021;23(1):40–55.
12. Mullowney MW, Duncan KR, Elsayed SS, Garg N, van der Hooff JJJ, Martin NI, et al. Artificial intelligence for natural product drug discovery. *Nat Rev Drug Discov*. 2023;22(11):895–916.
13. Wang H, Fu T, Du Y, Gao W, Huang K, Liu Z, et al. Scientific discovery in the age of artificial intelligence. *Nature*. 2023; 620(7972):47–60.
14. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med*. 2019;25(1):44–56.
15. Wong F, de la Fuente-Nunez C, Collins JJ. Leveraging artificial intelligence in the fight against infectious diseases. *Science*. 2023;381(6654):164–70.
16. World Health Organization. 2021 Antibacterial agents in clinical and preclinical development: an overview and analysis. Geneva: 2022. Available from: <https://www.who.int/publications/i/item/9789240047655>. Accessed 27 May 2022.
17. World Health Organization. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. 2017. Available from: <https://reliefweb.int/report/world/antibacterial-agents-clinical-development-analysisantibacterial-clinical-development-0>. Accessed 20 Sep 2017.
18. Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New beta-lactam-beta-lactamase inhibitor combinations. *Clin Microbiol Rev*. 2020;34(1):e00115–120.
19. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. *Lancet Infect Dis*. 2006;6(9):589–601.
20. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. *Clin Microbiol Rev*. 2008;21(3):449–65.
21. Nang SC, Azad MAK, Velkov T, Zhou QT, Li J. Rescuing the lastline polymyxins: achievements and challenges. *Pharmacol Rev*. 2021;73(2):679–728.
22. Li J, Nation RL. Old polymyxins are back: is resistance close?. *Clin Infect Dis*. 2006;43(5):663–4.
23. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. *Front Microbiol*. 2014;5:643.
24. Wang P, Zhang Q, Zhu Z, Pei H, Feng M, Sun T, et al. Comparing the population pharmacokinetics of and acute kidney injury due to polymyxin B in Chinese patients with or without renal insufficiency. *Antimicrob Agents Chemother*. 2021;65(2):e01900–1920.
25. Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: Is there any difference between colistimethate and polymyxin B?. *Antimicrob Agents Chemother*. 2017;61(3):e02319–2416.
26. Han L, Xu FM, Zhang XS, Zhang CH, Dai Y, Zhou ZY, et al. Trough polymyxin B plasma concentration is an independent risk factor for its nephrotoxicity. *Br J Clin Pharmacol*. 2022;88(3):1202–10.
27. Gai Z, Samodelov SL, Kullak-Ublick GA, Visentin M. Molecular mechanisms of colistin-induced nephrotoxicity. *Molecules*. 2019;24(3):653.
28. Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). *Pharmacotherapy*. 2019;39(1):10–39.
29. Lin YW, Zhou QT, Cheah SE, Zhao J, Chen K, Wang J, et al.

- Pharmacokinetics/pharmacodynamics of pulmonary delivery of colistin against *Pseudomonas aeruginosa* in a mouse lung infection model. *Antimicrob Agents Chemother*. 2017;61(3):e02025-2116.
30. Lin YW, Zhou Q, Onufrak NJ, Wirth V, Chen K, Wang J, et al. Aerosolized polymyxin b for treatment of respiratory tract infections: determination of pharmacokinetic-pharmacodynamic indices for aerosolized polymyxin B against *Pseudomonas aeruginosa* in a mouse lung infection model. *Antimicrob Agents Chemother*. 2017;61(8):e00211-217.
  31. Bruss J, Lister T, Gupta VK, Stone E, Morelli L, Lei Y, et al. Single- and multiple-ascending-dose study of the safety, tolerability, and pharmacokinetics of the polymyxin derivative SPR206. *Antimicrob Agents Chemother*. 2021;65(10):e0073921.
  32. Roberts KD, Zhu Y, Azad MAK, Han ML, Wang J, Wang L, et al. A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens. *Nat Commun*. 2022;13(1):1625.
  33. Lepak AJ, Wang W, Andes DR. Pharmacodynamic evaluation of MRX-8, a novel polymyxin, in the neutropenic mouse thigh and lung infection models against gram-negative pathogens. *Antimicrob Agents Chemother*. 2020;64(11):e01517-1520.
  34. Brown P, Abbott E, Abdulle O, Boakes S, Coleman S, Divall N, et al. Design of next generation polymyxins with lower toxicity: the discovery of SPR206. *ACS Infect Dis*. 2019;5(10):1645-56.
  35. Zhang Y, Zhao C, Wang Q, Wang X, Chen H, Li H, et al. Evaluation of the *in vitro* activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli. *J Antimicrob Chemother*. 2020;75(9):2609-15.
  36. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. *Clin Infect Dis*. 2008;47(10):1298-304.
  37. Liu X, Chen Y, Yang H, Li J, Yu J, Yu Z, et al. Acute toxicity is a dose-limiting factor for intravenous polymyxin B: a safety and pharmacokinetic study in healthy Chinese subjects. *J Infect*. 2021;82(2):207-15.
  38. Velkov T, Thompson PE, Nation RL, Li J. Structure-activity relationships of polymyxin antibiotics. *J Med Chem*. 2010;53(5):1898-916.
  39. Lenhard JR, Bulman ZP, Tsuji BT, Kaye KS. Shifting gears: the future of polymyxin antibiotics. *Antibiotics (Basel)*. 2019;8(2):42.
  40. Vaara M. Polymyxins and their potential next generation as therapeutic antibiotics. *Front Microbiol*. 2019;10:1689.
  41. Bodor N, Buchwald P. Soft drug design: general principles and recent applications. *Med Res Rev*. 2000;20(1):58-101.
  42. Fuhrmeister AS, Jones RN. The importance of antimicrobial resistance monitoring Worldwide and the origins of SENTRY antimicrobial surveillance program. *Open Forum Infect Dis*. 2019;6(Suppl 1):S1-4.
  43. Duncan LR, Wang W, Sader HS. *In vitro* potency and spectrum of the novel polymyxin MRX-8 tested against clinical isolates of gram-negative bacteria. *Antimicrob Agents Chemother*. 2022;66(5):e0013922.
  44. Wu S, Yin D, Zhi P, Guo Y, Yang Y, Zhu D, et al. *In vitro* activity of MRX-8 and comparators against clinical isolated gram-negative bacilli in China. *Front Cell Infect Microbiol*. 2022;12:829592.
  45. Bruno BM, Lim CS. Basics and recent advances in peptide and protein drug delivery. *Ther Deliv*. 2013;4(11):1443-67.
  46. Fjell CD, Hiss JA, Hancock RE, Schneider G. Designing antimicrobial peptides: form follows function. *Nat Rev Drug Discov*. 2011;11(1):37-51.
  47. Sharma D, Misba L, Khan AU. Antibiotics versus biofilm: an emerging battleground in microbial communities. *Antimicrob Resist Infect Control*. 2019;8:76.
  48. Raheem N, Straus SK. Mechanisms of action for antimicrobial peptides with antibacterial and antibiofilm functions. *Front Microbiol*. 2019;10:2866.
  49. Alalwani SM, Sierigk J, Herr C, Pinkenburg O, Gallo R, Vogelmeier C, et al. The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils. *Eur J Immunol*. 2010;40(4):1118-26.
  50. Boman HG. Antibacterial peptides: basic facts and emerging concepts. *J Intern Med*. 2003;254(3):197-215.
  51. Miyata T, Tokunaga F, Yoneya T, Yoshikawa K, Iwanaga S, Niwa M, et al. Antimicrobial peptides, isolated from horseshoe crab hemocytes, tachyplesin II, and polyphemusins I and II: chemical structures and biological activity. *J Biochem*. 1989;106(4):663-8.
  52. Zhang L, Scott MG, Yan H, Mayer LD, Hancock RE. Interaction of polyphemusin I and structural analogs with bacterial membranes, lipopolysaccharide, and lipid monolayers. *Biochemistry*. 2000;39(47):14504-14.
  53. Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. *Int J Radiat Oncol Biol Phys*. 2004;58(3):674-81.
  54. Ramachandran G, Tulapurkar ME, Harris KM, Arad G, Shirvan A, Shemesh R, et al. A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft-tissue infection induced by *Streptococcus pyogenes*. *J Infect Dis*. 2013;207(12):1869-77.
  55. Kasai M, Kumano K, Kurasawa K, Nakao A, Saito Y, Iwamoto I. Blockade of CD28/B7 interaction suppresses allergic eosinophilic inflammation in mice. *Int Arch Allergy Immunol*. 1998;117(Suppl 1):14-9.
  56. Arad G, Levy R, Nasie I, Hillman D, Rotfogel Z, Barash U, et al. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. *PLoS Biol*. 2011;9(9):e1001149.
  57. Mirzoeva S, Paunesku T, Wanzer MB, Shirvan A, Kaempfer R, Woloschak GE, et al. Single administration of p2TA (AB103), a CD28 antagonist peptide, prevents inflammatory and thrombotic reactions and protects against gastrointestinal injury in total-body irradiated mice. *PLoS One*. 2014;9(7):e101161.
  58. Bulger EM, Maier RV, Sperry J, Joshi M, Henry S, Moore FA, et al. A novel drug for treatment of necrotizing soft-tissue infections: a randomized clinical trial. *JAMA Surg*. 2014;149(6):528-36.
  59. Bulger EM, May AK, Robinson BRH, Evans DC, Henry S, Green JM, et al. A novel immune modulator for patients with Necrotizing Soft Tissue Infections (NSTI): results of a multicenter, phase 3 randomized controlled trial of reltecimod (AB 103). *Ann Surg*. 2020;272(3):469-78.
  60. Martin-Loeches I, Dale GE, Torres A. Murepavadin: a new antibiotic class in the pipeline. *Expert Rev Anti Infect Ther*. 2018;16(4):259-68.
  61. Srinivas N, Jetter P, Ueberbacher BJ, Werneburg M, Zerbe K, Steinmann J, et al. Peptidomimetic antibiotics target outer-membrane biogenesis in *Pseudomonas aeruginosa*. *Science*. 2010;327(5968):1010-3.
  62. Chaudhuri D, Ganesan R, Vogelaar A, Dughbaj MA, Beringer

- PM, Camarero JA. Chemical synthesis of a potent antimicrobial peptide murepavadin using a tandem native chemical ligation/desulfurization reaction. *J Org Chem*. 2021;86(21):15242–6.
63. Diez-Aguilar M, Ekkelenkamp M, Morosini MI, Huertas N, Del Campo R, Zamora J, et al. Anti-biofilm activity of murepavadin against cystic fibrosis *Pseudomonas aeruginosa* isolates. *J Antimicrob Chemother*. 2021;76(10):2578–85.
64. Sader HS, Flamm RK, Dale GE, Rhomberg PR, Castanheira M. Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR *Pseudomonas aeruginosa*. *J Antimicrob Chemother*. 2018;73(9):2400–4.
65. Dale GE, Halabi A, Petersen-Sylla M, Wach A, Zwingelstein C. Pharmacokinetics, tolerability, and safety of Murepavadin, a novel antipseudomonal antibiotic, in subjects with mild, moderate, or severe renal function impairment. *Antimicrob Agents Chemother*. 2018;62(9):e00490–518.
66. Ching T, Himmelstein DS, Beaulieu-Jones BK, Kalinin AA, Do BT, Way GP, et al. Opportunities and obstacles for deep learning in biology and medicine. *J R Soc Interface*. 2018;15(141):20170387.
67. Camacho DM, Collins KM, Powers RK, Costello JC, Collins JJ. Next-generation machine learning for biological networks. *Cell*. 2018;173(7):1581–92.
68. LeCun Y, Bengio Y, Hinton G. Deep learning. *Nature*. 2015;521(7553):436–44.
69. Zou J, Huss M, Abid A, Mohammadi P, Torkamani A, Telenti A. A primer on deep learning in genomics. *Nat Genet*. 2018;51(1):12–8.
70. Goodfellow IJ, Pouget-Abadie J, Mirza M, Xu B, Warde-Farley D, Ozair S, et al. Generative adversarial nets. *Advances in neural information processing systems*. 2014;2:2672–80. Available from: [https://proceedings.neurips.cc/paper\\_files/paper/2014/file/5ca3e9b122f61f8f06494c97b1afccf3-Paper.pdf](https://proceedings.neurips.cc/paper_files/paper/2014/file/5ca3e9b122f61f8f06494c97b1afccf3-Paper.pdf).
71. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. *Drug Discov Today*. 2021;26(1):80–93.
72. Lu M, Yin J, Zhu Q, Lin G, Mou M, Liu F, et al. Artificial intelligence in pharmaceutical sciences. *Engineering*. 2023. <https://doi.org/10.1016/j.eng.2023.01.014>.
73. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. *Drug Discov Today*. 2019;24(3):773–80.
74. Miethke M, Pieroni M, Weber T, Bronstrup M, Hammann P, Halby L, et al. Towards the sustainable discovery and development of new antibiotics. *Nat Rev Chem*. 2021;5(10):726–49.
75. Liu G, Stokes JM. A brief guide to machine learning for antibiotic discovery. *Curr Opin Microbiol*. 2022;69:102190.
76. Lluca T, Stokes JM. Antibiotic discovery in the artificial intelligence era. *Ann N Y Acad Sci*. 2023;1519(1):74–93.
77. Krentzel D, Shorte SL, Zimmer C. Deep learning in image-based phenotypic drug discovery. *Trends Cell Biol*. 2023;33(7):538–54.
78. Talat A, Khan AU. Artificial intelligence as a smart approach to develop antimicrobial drug molecules: a paradigm to combat drug-resistant infections. *Drug Discov Today*. 2023;28(4):103491.
79. Urbina F, Puhl AC, Ekins S. Recent advances in drug repurposing using machine learning. *Curr Opin Chem Biol*. 2021;65:74–84.
80. Gould K. Antibiotics: from prehistory to the present day. *J Antimicrob Chemother*. 2016;71(3):572–5.
81. Medema MH, de Rond T, Moore BS. Mining genomes to illuminate the specialized chemistry of life. *Nat Rev Genet*. 2021;22(9):553–71.
82. Blin K, Shaw S, Augustijn HE, Reitz ZL, Biermann F, Alanjary M, et al. antiSMASH 7.0: new and improved predictions for detection, regulation, chemical structures and visualisation. *Nucleic Acids Res*. 2023;51(W1):W46–50.
83. Mungan MD, Alanjary M, Blin K, Weber T, Medema MH, Ziemert N. ARTS 2.0: feature updates and expansion of the antibiotic resistant target seeker for comparative genome mining. *Nucleic Acids Res*. 2020;48(W1):W546–52.
84. Hannigan GD, Prihoda D, Palicka A, Soukup J, Klempir O, Rampula L, et al. A deep learning genome-mining strategy for biosynthetic gene cluster prediction. *Nucleic Acids Res*. 2019;47(18):e110.
85. Merwin NJ, Mousa WK, Dejong CA, Skinnider MA, Cannon MJ, Li H, et al. DeepRiPP integrates multiomics data to automate discovery of novel ribosomally synthesized natural products. *Proc Natl Acad Sci U S A*. 2020;117(1):371–80.
86. Skinnider MA, Johnston CW, Gunabalasingam M, Merwin NJ, Kieliszek AM, MacLellan RJ, et al. Comprehensive prediction of secondary metabolite structure and biological activity from microbial genome sequences. *Nat Commun*. 2020;11(1):6058.
87. Walker AS, Clardy J. A machine learning bioinformatics method to predict biological activity from biosynthetic gene clusters. *J Chem Inf Model*. 2021;61(6):2560–71.
88. Johnson EO, LaVerriere E, Office E, Stanley M, Meyer E, Kawate T, et al. Large-scale chemical–genetics yields new *M. tuberculosis* inhibitor classes. *Nature*. 2019;571(7763):72–8.
89. Liu G, Catacutan DB, Rathod K, Swanson K, Jin W, Mohammed JC, et al. Deep learning-guided discovery of an antibiotic targeting *Acinetobacter baumannii*. *Nat Chem Biol*. 2023;19(11):1342–50.
90. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. *Nature*. 2021;596(7873):583–9.
91. Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, et al. AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. *Nucleic Acids Res*. 2022;50(D1):D439–44.
92. Baek M, DiMaio F, Anishchenko I, Dauparas J, Ovchinnikov S, Lee GR, et al. Accurate prediction of protein structures and interactions using a three-track neural network. *Science*. 2021;373(6557):871–6.
93. Wong F, Krishnan A, Zheng EJ, Stärk H, Manson AL, Earl AM, et al. Benchmarking AlphaFold-enabled molecular docking predictions for antibiotic discovery. *Mol Syst Biol*. 2022;18(9):e11081.
94. Karelina M, Noh JJ, Dror RO. How accurately can one predict drug binding modes using AlphaFold models?. *Elife*. 2023. Available from: <https://elifesciences.org/reviewed-preprints/89386>.
95. Fang X, Wang F, Liu L, He J, Lin D, Xiang Y, et al. A method for multiple-sequence-alignment-free protein structure prediction using a protein language model. *Nat Mach Intell*. 2023;5(10):1087–96.
96. Ourmazd A, Moffat K, Lattman ED. Structural biology is solved—Now what?. *Nat Methods*. 2022;19(1):11–2.
97. Price MN, Wetmore KM, Waters RJ, Callaghan M, Ray J, Liu H, et al. Mutant phenotypes for thousands of bacterial genes of unknown function. *Nature*. 2018;557(7706):503–9.
98. Gligorijević V, Renfrew PD, Kosciolk T, Leman JK, Berenberg D, Vatanen T, et al. Structure-based protein function prediction using graph convolutional networks. *Nat Commun*. 2021;12(1):3168.
99. Mistry J, Chuguransky S, Williams L, Qureshi M, Salazar GA, Sonnhammer ELL, et al. Pfam: the protein families database in

2021. *Nucleic Acids Res.* 2021;49(D1):D412–9.
100. Bileschi ML, Belanger D, Bryant DH, Sanderson T, Carter B, Sculley D, et al. Using deep learning to annotate the protein universe. *Nat Biotechnol.* 2022;40(6):932–7.
101. Hamamsy T, Morton JT, Blackwell R, Berenberg D, Carriero N, Gligorijevic V, et al. Protein remote homology detection and structural alignment using deep learning. *Nat Biotechnol.* 2023. <https://doi.org/10.1038/s41587-023-01917-2>.
102. Mansbach RA, Leus IV, Mehla J, Lopez CA, Walker JK, Rybenkov VV, et al. Machine learning algorithm identifies an antibiotic vocabulary for permeating Gram-negative bacteria. *J Chem Inf Model.* 2020;60(6):2838–47.
103. Stahl N, Falkman G, Karlsson A, Mathiason G, Bostrom J. Deep reinforcement learning for multiparameter optimization in *de novo* drug design. *J Chem Inf Model.* 2019;59(7):3166–76.
104. Segler MHS, Preuss M, Waller MP. Planning chemical syntheses with deep neural networks and symbolic AI. *Nature.* 2018;555(7698):604–10.
105. Morselli Gysi D, do Valle Í, Zitnik M, Ameli A, Gan X, Varol O, et al. Network medicine framework for identifying drug-repurposing opportunities for COVID-19. *Proc Natl Acad Sci U S A.* 2021;118(19):e2025581118.
106. Farha MA, Brown ED. Drug repurposing for antimicrobial discovery. *Nat Microbiol.* 2019;4(4):565–77.
107. Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE, et al. The drug repurposing hub: a next-generation drug library and information resource. *Nat Med.* 2017;23(4):405–8.
108. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A deep learning approach to antibiotic discovery. *Cell.* 2020;180(4):688–702.e13.
109. Booq RY, Tawfik EA, Alfassam HA, Alfahad AJ, Alyamani EJ. Assessment of the antibacterial efficacy of halicin against pathogenic bacteria. *Antibiotics (Basel).* 2021;10(12):1480.
110. Ekins S, Reynolds RC, Kim H, Koo MS, Ekonomidis M, Talaue M, et al. Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery. *Chem Biol.* 2013;20(3):370–8.
111. Li WX, Tong X, Yang PP, Zheng Y, Liang JH, Li GH, et al. Screening of antibacterial compounds with novel structure from the FDA approved drugs using machine learning methods. *Aging.* 2022;14(3):1448–72.
112. Zhang QY, Yan ZB, Meng YM, Hong XY, Shao G, Ma JJ, et al. Antimicrobial peptides: mechanism of action, activity and clinical potential. *Mil Med Res.* 2021;8(1):48.
113. Cardoso MH, Orozco RQ, Rezende SB, Rodrigues G, Oshiro KGN, Cândido ES, et al. Computer-aided design of antimicrobial peptides: are we generating effective drug candidates?. *Front Microbiol.* 2020;10:3097.
114. Yan J, Bhadra P, Li A, Sethiya P, Qin L, Tai HK, et al. Deep-AmPEP30: improve short antimicrobial peptides prediction with deep learning. *Mol Ther Nucleic Acids.* 2020;20:882–94.
115. Kavousi K, Bagheri M, Behrouzi S, Vafadar S, Atanaki FF, Lotfabadi BT, et al. IAMPE: NMR-assisted computational prediction of antimicrobial peptides. *J Chem Inf Model.* 2020;60(10):4691–701.
116. Yu L, Jing R, Liu F, Luo J, Li Y. DeepACP: a novel computational approach for accurate identification of anticancer peptides by deep learning algorithm. *Mol Ther Nucleic Acids.* 2020;22:862–70.
117. Bin Hafeez A, Jiang X, Bergen PJ, Zhu Y. Antimicrobial peptides: an update on classifications and databases. *Int J Mol Sci.* 2021;22(21):11691.
118. Fjell CD, Hancock RE, Cherkasov A. AMPper: a database and an automated discovery tool for antimicrobial peptides. *Bioinformatics.* 2007;23(9):1148–55.
119. Brahmachary M, Krishnan SP, Koh JL, Khan AM, Seah SH, Tan TW, et al. ANTIMIC: a database of antimicrobial sequences. *Nucleic Acids Res.* 2004;32(Database issue):D586–9.
120. Robinson JA. Protein epitope mimetics as anti-infectives. *Curr Opin Chem Biol.* 2011;15(3):379–86.
121. Zerbe K, Moehle K, Robinson JA. Protein epitope mimetics: from new antibiotics to supramolecular synthetic vaccines. *Acc Chem Res.* 2017;50(6):1323–31.
122. Mátyus EK, C. Tieleman DP. Computer simulation of antimicrobial peptides. *Curr Med Chem.* 2007;14:2789–98.
123. Rozek A, Powers JPS, Friedrich CL, Hancock REW. Structure-based design of an indolicidin peptide analogue with increased protease stability. *Biochemistry.* 2003;42(48):14130–8.
124. Wu X, Wang Z, Li X, Fan Y, He G, Wan Y, et al. *In vitro* and *in vivo* activities of antimicrobial peptides developed using an amino acid-based activity prediction method. *Antimicrob Agents Chemother.* 2014;58(9):5342–9.
125. Hirschberg J, Manning CD. Advances in natural language processing. *Science.* 2015;349(6245):261–6.
126. Ma Y, Guo Z, Xia B, Zhang Y, Liu X, Yu Y, et al. Identification of antimicrobial peptides from the human gut microbiome using deep learning. *Nat Biotechnol.* 2022;40(6):921–31.
127. Maasch J, Torres MDT, Melo MCR, de la Fuente-Nunez C. Molecular de-extinction of ancient antimicrobial peptides enabled by machine learning. *Cell Host Microbe.* 2023;31(8):1260–74.
128. Huang J, Xu Y, Xue Y, Huang Y, Li X, Chen X, et al. Identification of potent antimicrobial peptides via a machine-learning pipeline that mines the entire space of peptide sequences. *Nat Biomed Eng.* 2023;7(6):797–810.
129. Blaschke T, Olivecrona M, Engkvist O, Bajorath J, Chen H. Application of generative autoencoder in *de novo* molecular design. *Mol Inform.* 2018;37(1–2):1700123.
130. Das P, Sercu T, Wadhawan K, Padhi I, Gehrman S, Cipcigan F, et al. Accelerated antimicrobial discovery via deep generative models and molecular dynamics simulations. *Nat Biomed Eng.* 2021;5(6):613–23.
131. Szymczak P, Mozejko M, Grzegorzek T, Jurczak R, Bauer M, Neubauer D, et al. Discovering highly potent antimicrobial peptides with deep generative model HydrAMP. *Nat Commun.* 2023;14(1):1453.
132. Pandi A, Adam D, Zare A, Trinh VT, Schaefer SL, Burt M, et al. Cell-free biosynthesis combined with deep learning accelerates *de novo*-development of antimicrobial peptides. *Nat Commun.* 2023;14(1):7197.
133. Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. *Clin Microbiol Rev.* 2019;32(2):e00066-118.
134. Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: from biological mechanisms to future directions. *Cell.* 2023;186(1):17–31.
135. Shkoporov AN, Clooney AG, Sutton TDS, Ryan FJ, Daly KM, Nolan JA, et al. The human gut virome is highly diverse, stable, and individual specific. *Cell Host Microbe.* 2019;26(4):527–41.e5.
136. Fishbein SRS, Mahmud B, Dantas G. Antibiotic perturbations to the gut microbiome. *Nat Rev Microbiol.* 2023;21(12):772–88.
137. Liu G, Thomsen LE, Olsen JE. Antimicrobial-induced horizontal transfer of antimicrobial resistance genes in bacteria: a mini-review. *J Antimicrob Chemother.* 2021;77(3):556–67.
138. Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA,

- Ford K, Harris K, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant *Mycobacterium abscessus*. *Nat Med*. 2019;25(5):730–3.
139. Leitner L, Ujmajuridze A, Chanishvili N, Goderdzishvili M, Chkonia I, Rigvava S, et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. *Lancet Infect Dis*. 2021;21(3):427–36.
140. Uyttebroek S, Chen B, Onsea J, Ruythooren F, Debaveye Y, Devolder D, et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. *Lancet Infect Dis*. 2022;22(8):e208–20.
141. Onallah H, Hazan R, Nir-Paz R, Brownstein MJ, Fackler JR, Horne BA, et al. Refractory *Pseudomonas aeruginosa* infections treated with phage PASA16: a compassionate use case series. *Medicine*. 2023;4(9):600-11.e4.
142. Camarillo-Guerrero LF, Almeida A, Rangel-Pineros G, Finn RD, Lawley TD. Massive expansion of human gut bacteriophage diversity. *Cell*. 2021;184(4):1098-109.e9.
143. Bajjya N, Dhall A, Aggarwal S, Raghava GPS. Advances in the field of phage-based therapy with special emphasis on computational resources. *Brief Bioinform*. 2023;24(1):bbac574.
144. Ho SFS, Wheeler NE, Millard AD, van Schaik W. Gauge your phage: benchmarking of bacteriophage identification tools in metagenomic sequencing data. *Microbiome*. 2023;11(1):84.
145. Auslander N, Gussow AB, Benler S, Wolf YI, Koonin EV. Seeker: alignment-free identification of bacteriophage genomes by deep learning. *Nucleic Acids Res*. 2020;48(21):e121.
146. Kieft K, Zhou Z, Anantharaman K. VIBRANT: automated recovery, annotation and curation of microbial viruses, and evaluation of viral community function from genomic sequences. *Microbiome*. 2020;8(1):90.
147. Guo J, Bolduc B, Zayed AA, Varsani A, Dominguez-Huerta G, Delmont TO, et al. VirSorter2: a multi-classifier, expert-guided approach to detect diverse DNA and RNA viruses. *Microbiome*. 2021;9(1):37.
148. Siren K, Millard A, Petersen B, Gilbert MTP, Clokie MRJ, Sicheritz-Ponten T. Rapid discovery of novel prophages using biological feature engineering and machine learning. *NAR Genom Bioinform*. 2021;3(1):lqaa109.
149. Gauthier CH, Abad L, Venbakkam AK, Malnak J, Russell Daniel A, Hatfull GF. DEPhT: a novel approach for efficient prophage discovery and precise extraction. *Nucleic Acids Res*. 2022;50(13):e75.
150. Pinto Y, Chakraborty M, Jain N, Bhatt AS. Phage-inclusive profiling of human gut microbiomes with Phanta. *Nat Biotechnol*. 2023. <https://doi.org/10.1038/s41587-023-01799-4>.
151. Seguritan V, Alves N Jr, Arnoult M, Raymond A, Lorimer D, Burgin AB Jr, et al. Artificial neural networks trained to detect viral and phage structural proteins. *PLoS Comput Biol*. 2012;8(8):e1002657.
152. Cantu VA, Salamon P, Seguritan V, Redfield J, Salamon D, Edwards RA, et al. PhANNs, a fast and accurate tool and web server to classify phage structural proteins. *PLoS Comput Biol*. 2020;16(11):e1007845.
153. Thung TY, White ME, Dai W, Wilksch JJ, Bamert RS, Rocker A, et al. Component parts of bacteriophage virions accurately defined by a machine learning approach built on. *mSystems*. 2021;6(3):e0024221.
154. Ahmad S, CHARONKwan P, Quinn JMW, Moni MA, Hasan MM, Lio P, et al. SCORPION is a stacking-based ensemble learning framework for accurate prediction of phage virion proteins. *Sci Rep*. 2022;12(1):4106.
155. Wang W, Ren J, Tang K, Dart E, Ignacio-Espinoza JC, Fuhrman JA, et al. A network-based integrated framework for predicting virus-prokaryote interactions. *NAR Genom Bioinform*. 2020;2(2):lqaa044.
156. Leite DMC, Brochet X, Resch G, Que YA, Neves A, Peña-Reyes C. Computational prediction of inter-species relationships through omics data analysis and machine learning. *BMC Bioinform*. 2018;19(S14):420.
157. Shang J, Sun Y. Predicting the hosts of prokaryotic viruses using GCN-based semi-supervised learning. *BMC Biol*. 2021;19(1):250.
158. McNair K, Bailey BA, Edwards RA. PHACTS, a computational approach to classifying the lifestyle of phages. *Bioinformatics*. 2012;28(5):614–8.
159. Hockenberry AJ, Wilke CO. BACPHLIP: predicting bacteriophage lifestyle from conserved protein domains. *PeerJ*. 2021;9:e11396.
160. Shang J, Tang X, Sun Y. PhaTYP: predicting the lifestyle for bacteriophages using BERT. *Brief Bioinform*. 2023;24(1):bbac487.
161. Cox SD, Mann CM, Markham JL, Bell HC, Gustafson JE, Warmington JR, et al. The mode of antimicrobial action of the essential oil of *Melaleuca alternifolia* (tea tree oil). *J Appl Microbiol*. 2000;88(1):170–5.
162. Tariq S, Wani S, Rasool W, Shafi K, Bhat MA, Prabhakar A, et al. A comprehensive review of the antibacterial, antifungal and antiviral potential of essential oils and their chemical constituents against drug-resistant microbial pathogens. *Microb Pathog*. 2019;134:103580.
163. Daynac M, Cortes-Cabrera A, Prieto JM. Application of artificial intelligence to the prediction of the antimicrobial activity of essential oils. *Evid Based Complement Altern Med*. 2015;2015:561024.
164. Pal C, Bengtsson-Palme J, Rensing C, Kristiansson E, Larsson DG. BacMet: antibacterial biocide and metal resistance genes database. *Nucleic Acids Res*. 2014;42(Database issue):D737–43.
165. Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Boucharde M, Edalatmand A, et al. CARD 2020: antibiotic resistance surveillance with the comprehensive antibiotic resistance database. *Nucleic Acids Res*. 2020;48(D1):D517–25.
166. Reimer LC, Sardà Carbasse J, Koblit J, Ebeling C, Podstawka A, Overmann J. BacDive in 2022: the knowledge base for standardized bacterial and archaeal data. *Nucleic Acids Res*. 2022;50(D1):D741–6.
167. Jesus TF, Ribeiro-Goncalves B, Silva DN, Bortolaia V, Ramirez M, Carrico JA. Plasmid ATLAS: plasmid visual analytics and identification in high-throughput sequencing data. *Nucleic Acids Res*. 2019;47(D1):D188–94.
168. Liu B, Zheng D, Zhou S, Chen L, Yang J. VFDB 2022: a general classification scheme for bacterial virulence factors. *Nucleic Acids Res*. 2022;50(D1):D912–7.
169. Moradigaravand D, Palm M, Farewell A, Mustonen V, Warringer J, Parts L. Prediction of antibiotic resistance in *Escherichia coli* from large-scale pan-genome data. *PLoS Comput Biol*. 2018;14(12):e1006258.
170. Ren Y, Chakraborty T, Doijad S, Falgenhauer L, Falgenhauer J, Goesmann A, et al. Prediction of antimicrobial resistance based on whole-genome sequencing and machine learning. *Bioinformatics*. 2022;38(2):325–34.
171. Tang R, Luo R, Tang S, Song H, Chen X. Machine learning in predicting antimicrobial resistance: a systematic review and

- meta-analysis. *Int J Antimicrob Agents*. 2022;60(5–6):106684.
172. Davis JJ, Wattam AR, Aziz RK, Brettin T, Butler R, Butler RM, et al. The PATRIC Bioinformatics Resource Center: expanding data and analysis capabilities. *Nucleic Acids Res*. 2020;48(D1):D606–12.
173. Davis JJ, Boisvert S, Brettin T, Kenyon RW, Mao C, Olson R, et al. Antimicrobial resistance prediction in PATRIC and RAST. *Sci Rep*. 2016;6:27930.
174. Her HL, Wu YW. A pan-genome-based machine learning approach for predicting antimicrobial resistance activities of the *Escherichia coli* strains. *Bioinformatics*. 2018;34(13):i89–95.
175. Nguyen M, Long SW, McDermott PF, Olsen RJ, Olson R, Stevens RL, et al. Using machine learning to predict antimicrobial MICs and associated genomic features for nontyphoidal *Salmonella*. *J Clin Microbiol*. 2019;57(2):e01260–1318.
176. Bhattacharyya RP, Bandyopadhyay N, Ma P, Son SS, Liu J, He LL, et al. Simultaneous detection of genotype and phenotype enables rapid and accurate antibiotic susceptibility determination. *Nat Med*. 2019;25(12):1858–64.
177. Khaledi A, Weimann A, Schniederjans M, Asgari E, Kuo TH, Oliver A, et al. Predicting antimicrobial resistance in *Pseudomonas aeruginosa* with machine learning-enabled molecular diagnostics. *EMBO Mol Med*. 2020;12(3):e10264.
178. Arango-Argoty G, Garner E, Pruden A, Heath LS, Vikesland P, Zhang L. DeepARG: a deep learning approach for predicting antibiotic resistance genes from metagenomic data. *Microbiome*. 2018;6(1):23.
179. Rahman SF, Olm MR, Morowitz MJ, Banfield JF, Segata N. Machine learning leveraging genomes from metagenomes identifies influential antibiotic resistance genes in the infant gut microbiome. *mSystems*. 2018;3(1):e00123–17.
180. Macesic N, Bear Don't Walk OJ IV, Pe'er I, Tatonetti NP, Peleg AY, Uhlemann AC. Predicting phenotypic polymyxin resistance in *Klebsiella pneumoniae* through machine learning analysis of genomic data. *mSystems*. 2020;5(3):e00656–19.
181. Sunuwar J, Azad RK. A machine learning framework to predict antibiotic resistance traits and yet unknown genes underlying resistance to specific antibiotics in bacterial strains. *Brief Bioinform*. 2021;22(6):bbab179.
182. Ortmayr K, de la Cruz MR, Zampieri M. Expanding the search for small molecule antibacterials by multidimensional profiling. *Nat Chem Biol*. 2022;18(6):584–95.
183. Zoffmann S, Vercruyse M, Benmansour F, Maunz A, Wolf L, Blum Marti R, et al. Machine learning-powered antibiotics phenotypic drug discovery. *Sci Rep*. 2019;9(1):5013.
184. Nonejuie P, Burkart M, Pogliano K, Pogliano J. Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules. *Proc Natl Acad Sci U S A*. 2013;110(40):16169–74.
185. Qiao C, Li D, Guo Y, Liu C, Jiang T, Dai Q, et al. Evaluation and development of deep neural networks for image super-resolution in optical microscopy. *Nat Methods*. 2021;18(2):194–202.
186. Smith TC, Pullen KM, Olson MC, McNellis ME, Richardson I, Hu S, et al. Morphological profiling of tubercle bacilli identifies drug pathways of action. *Proc Natl Acad Sci U S A*. 2020;117(31):18744–53.
187. Martin JK, Sheehan JP, Bratton BP, Moore GM, Mateus A, Li SHJ, et al. A dual-mechanism antibiotic kills gram-negative bacteria and avoids drug resistance. *Cell*. 2020;181(7):1518–32.e14.
188. Ma S, Jaipalli S, Larkins-Ford J, Lohmiller J, Aldridge BB, Sherman DR, et al. Transcriptomic signatures predict regulators of drug synergy and clinical regimen efficacy against tuberculosis. *mBio*. 2019;10(6):e02627–19.
189. Weis C, Cuenod A, Rieck B, Dubuis O, Graf S, Lang C, et al. Direct antimicrobial resistance prediction from clinical MALDI-TOF mass spectra using machine learning. *Nat Med*. 2022;28(1):164–74.
190. Zampieri M, Szappanos B, Buchieri MV, Trauner A, Piazza I, Picotti P, et al. High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds. *Sci Transl Med*. 2018;10(429):eaal3973.
191. Anglada-Girotto M, Handschin G, Ortmayr K, Campos AI, Gillet L, Manfredi P, et al. Combining CRISPRi and metabolomics for functional annotation of compound libraries. *Nat Chem Biol*. 2022;18(5):482–91.
192. Yang JH, Wright SN, Hamblin M, McCloskey D, Alcantar MA, Schrubbers L, et al. A White-box machine learning approach for revealing antibiotic mechanisms of action. *Cell*. 2019;177(6):1649–61.e9.
193. Machado D, Andrejev S, Tramontano M, Patil KR. Fast automated reconstruction of genome-scale metabolic models for microbial species and communities. *Nucleic Acids Res*. 2018;46(15):7542–53.
194. Fu M, Gong Z, Li C, Ling K, Zhu Y, Li H, et al. Appropriate use of antibiotics for acute respiratory infections at primary healthcare facilities in China: a nationwide cross-sectional study from 2017 to 2019. *Lancet Reg Health West Pac*. 2023;40:100880.
195. Anahtar MN, Yang JH, Kanjilal S. Applications of machine learning to the problem of antimicrobial resistance: an emerging model for translational research. *J Clin Microbiol*. 2021;49(7):e0126020.
196. Yelin I, Snitser O, Novich G, Katz R, Tal O, Parizade M, et al. Personal clinical history predicts antibiotic resistance of urinary tract infections. *Nat Med*. 2019;25(7):1143–52.
197. Kanjilal S, Oberst M, Boominathan S, Zhou H, Hooper DC, Sontag D. A decision algorithm to promote outpatient antimicrobial stewardship for uncomplicated urinary tract infection. *Sci Transl Med*. 2020;12(568):eaay5067.
198. Moran E, Robinson E, Green C, Keeling M, Collyer B. Towards personalized guidelines: using machine-learning algorithms to guide antimicrobial selection. *J Antimicrob Chemother*. 2020;75(9):2677–80.
199. Feretzakis G, Loupelis E, Sakagianni A, Kalles D, Martsoukou M, Lada M, et al. Using machine learning techniques to aid empirical antibiotic therapy decisions in the intensive care unit of a general hospital in Greece. *Antibiotics*. 2020;9(2):50.
200. Osman M, Mahieu R, Eveillard M. Machine-learning approaches prevent post-treatment resistance-gaining bacterial recurrences. *Trends Microbiol*. 2022;30(7):612–4.
201. Stracy M, Snitser O, Yelin I, Amer Y, Parizade M, Katz R, et al. Minimizing treatment-induced emergence of antibiotic resistance in bacterial infections. *Science*. 2022;375(6583):889–94.
202. Crits-Christoph A, Hallowell HA, Koutouvalis K, Suez J. Good microbes, bad genes? The dissemination of antimicrobial resistance in the human microbiome. *Gut Microbes*. 2022;14(1):2055944.
203. Gainza P, Wehrle S, Van Hall-Beauvais A, Marchand A, Scheck A, Hartevelde Z, et al. De novo design of protein interactions with learned surface fingerprints. *Nature*. 2023;617(7959):176–84.
204. Atz K, Grisoni F, Schneider G. Geometric deep learning on molecular representations. *Nat Mach Intell*. 2021;3(12):1023–32.
205. Geirhos R, Jacobsen J-H, Michaelis C, Zemel R, Brendel W, Bethge M, et al. Shortcut learning in deep neural networks. *Nat Mach*

- Intell. 2020;2(11):665–73.
206. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. *Nat Rev Drug Discov.* 2019;18(6):463–77.
207. Jimenez-Luna J, Grisoni F, Weskamp N, Schneider G. Artificial intelligence in drug discovery: recent advances and future perspectives. *Expert Opin Drug Discov.* 2021;16(9):949–59.
208. Rudin C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. *Nat Mach Intell.* 2019;1(5):206–15.
209. Jiménez-Luna J, Grisoni F, Schneider G. Drug discovery with explainable artificial intelligence. *Nat Mach Intell.* 2020;2(10):573–84.
210. Mock ME, S. Langmead, C. Russell, A. AI can help to speed up drug discovery—but only if we give it the right data. *Nature.* 2023;621(7979):467–70.
211. Warnat-Herresthal S, Schultze H, Shastry KL, Manamohan S, Mukherjee S, Garg V, et al. Swarm learning for decentralized and confidential clinical machine learning. *Nature.* 2021;594(7862):265–70.
212. Van de Sande B, Lee JS, Mutasa-Gottgens E, Naughton B, Bacon W, Manning J, et al. Applications of single-cell RNA sequencing in drug discovery and development. *Nat Rev Drug Discov.* 2023;22(6):496–520.
213. Ma P, Amemiya HM, He LL, Gandhi SJ, Nicol R, Bhattacharyya RP, et al. Bacterial droplet-based single-cell RNA-seq reveals antibiotic-associated heterogeneous cellular states. *Cell.* 2023;186(4):877–91.e14.
214. Melo MCR, Maasch J, de la Fuente-Nunez C. Accelerating antibiotic discovery through artificial intelligence. *Commun Biol.* 2021;4(1):1050.

<https://doi.org/10.1186/s40779-024-00510-1>

**Cite this article as:** Liu GY, Yu D, Fan MM, Zhang X, Jin ZY, Tang C, et al. Antimicrobial resistance crisis: could artificial intelligence be the solution?. *Mil Med Res.* 2024;11(1):7.